BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821-829. [PMID: 22727733 DOI: 10.1016/j.jhep.2012.06.014] [Cited by in Crossref: 473] [Cited by in F6Publishing: 444] [Article Influence: 52.6] [Reference Citation Analysis]
Number Citing Articles
1 Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Benvegnù L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015;61:184-90. [DOI: 10.1002/hep.27443] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 12.4] [Reference Citation Analysis]
2 Kaibori M, Matsushima H, Ishizaki M, Kosaka H, Matsui K, Nakatani M, Kariya S, Yamaguchi T, Yoshida K, Yoshii K, Sekimoto M. The Impact of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion. Cancer Invest 2021;:1-9. [PMID: 34236269 DOI: 10.1080/07357907.2021.1952594] [Reference Citation Analysis]
3 De Matteis S, Ghetti M, Gramantieri L, Marisi G, Casadei-Gardini A. Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV. Onco Targets Ther 2021;14:4305-8. [PMID: 34366674 DOI: 10.2147/OTT.S312748] [Reference Citation Analysis]
4 Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer 2019;7:333. [PMID: 31783782 DOI: 10.1186/s40425-019-0824-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 19.5] [Reference Citation Analysis]
5 Wang J, Luo J, Yin X, Huang W, Cao H, Wang G, Wang J, Zhou J. Jiedu Granule Combined with Transcatheter Arterial Chemoembolization and Gamma Knife Radiosurgery in Treating Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Biomed Res Int 2019;2019:4696843. [PMID: 31341898 DOI: 10.1155/2019/4696843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Chang CC, Dinh TK, Lee YA, Wang FN, Sung YC, Yu PL, Chiu SC, Shih YC, Wu CY, Huang YD, Wang J, Lu TT, Wan D, Chen Y. Nanoparticle Delivery of MnO2 and Antiangiogenic Therapy to Overcome Hypoxia-Driven Tumor Escape and Suppress Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2020;12:44407-19. [PMID: 32865389 DOI: 10.1021/acsami.0c08473] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
7 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in Crossref: 260] [Cited by in F6Publishing: 237] [Article Influence: 43.3] [Reference Citation Analysis]
8 Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Dig Liver Dis. 2013;45:408-413. [PMID: 23182599 DOI: 10.1016/j.dld.2012.10.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
9 Bruera G, Cannita K, Giordano AV, Manetta R, Vicentini R, Carducci S, Saltarelli P, Iapadre N, Coletti G, Ficorella C. Multidisciplinary management of hepatocellular carcinoma in clinical practice. Biomed Res Int. 2014;2014:806391. [PMID: 24900987 DOI: 10.1155/2014/806391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
10 Lee EW, Alanis L, Cho SK, Saab S. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. Korean J Radiol. 2016;17:472-488. [PMID: 27390539 DOI: 10.3348/kjr.2016.17.4.472] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
11 Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers (Basel). 2019;11. [PMID: 31216701 DOI: 10.3390/cancers11060841] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
12 Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res. 2013;43:147-154. [PMID: 23145926 DOI: 10.1111/j.1872-034x.2012.01113] [Reference Citation Analysis]
13 Assenat E, Pageaux GP, Thézenas S, Peron JM, Bécouarn Y, Seitz JF, Merle P, Blanc JF, Bouché O, Ramdani M, Poujol S, de Forges H, Ychou M, Boige V. Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. Br J Cancer 2019;120:896-902. [PMID: 30944458 DOI: 10.1038/s41416-019-0443-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
14 Loong HH, Yeo W. Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. Onco Targets Ther 2014;7:575-85. [PMID: 24790457 DOI: 10.2147/OTT.S46019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
15 Park JH, Kim HY, Lee A, Seo YK, Kim IH, Park ET, Kang MS, Park SJ, Park S. Enlightening the Immune Mechanism of the Abscopal Effect in a Murine HCC Model and Overcoming the Late Resistance With Anti-PD-L1. Int J Radiat Oncol Biol Phys 2021;110:510-20. [PMID: 33383126 DOI: 10.1016/j.ijrobp.2020.12.031] [Reference Citation Analysis]
16 Tovoli F, Negrini G, Benevento F, Faggiano C, Goio E, Granito A. Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepat Oncol 2018;5:HEP01. [PMID: 30302192 DOI: 10.2217/hep-2017-0020] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
17 Chen T, Xiong J, Yang C, Shan L, Tan G, Yu L, Tan Y. Silencing of FOXM1 transcription factor expression by adenovirus-mediated RNA interference inhibits human hepatocellular carcinoma growth. Cancer Gene Ther 2014;21:133-8. [DOI: 10.1038/cgt.2014.8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
18 Chauhan N, Bukovcan J, Boucher E, Cosgrove D, Edeline J, Hamilton B, Kulik L, Master F, Salem R. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial. JMIR Res Protoc 2018;7:e11234. [PMID: 30111528 DOI: 10.2196/11234] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
19 Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma 2021;8:387-401. [PMID: 34012929 DOI: 10.2147/JHC.S300182] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
20 Sha M, Jeong S, Chen XS, Tong Y, Cao J, Sun HY, Xia L, Xu N, Wang X, Han LZ, Xi ZF, Zhang JJ, Kong XN, Xia Q. Expression of VEGFR-3 in intrahepatic cholangiocarcinoma correlates with unfavorable prognosis through lymphangiogenesis. Int J Biol Sci 2018;14:1333-42. [PMID: 30123080 DOI: 10.7150/ijbs.26045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
21 Cappelli A, Pettinato C, Golfieri R. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma 2014;1:163-82. [PMID: 27508185 DOI: 10.2147/JHC.S50472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
22 Somma F, Stoia V, Serra N, D'Angelo R, Gatta G, Fiore F. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. PLoS One 2019;14:e0216935. [PMID: 31141552 DOI: 10.1371/journal.pone.0216935] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
23 Wong LS, Wong CM. Decoding the Roles of Long Noncoding RNAs in Hepatocellular Carcinoma. Int J Mol Sci 2021;22:3137. [PMID: 33808647 DOI: 10.3390/ijms22063137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Rota Caremoli E, Labianca R. Tivantinib: critical review with a focus on hepatocellular carcinoma. Expert Opin Investig Drugs. 2014;23:1563-1574. [PMID: 25307444 DOI: 10.1517/13543784.2014.949339] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
25 Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau G, Luca A, del Arbol LR, Leberre M, Niu W, Nicholson K, Meinhardt G, Bruix J. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. Journal of Hepatology 2016;64:1090-8. [DOI: 10.1016/j.jhep.2016.01.012] [Cited by in Crossref: 296] [Cited by in F6Publishing: 271] [Article Influence: 59.2] [Reference Citation Analysis]
26 Siegel AB, El-Khoueiry AB, Finn RS, Guthrie KA, Goyal A, Venook AP, Blanke CD, Verna EC, Dove L, Emond J, Kato T, Samstein B, Busuttil R, Remotti H, Coffey A, Brown RS Jr. Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma. Liver Cancer 2015;4:115-25. [PMID: 26020033 DOI: 10.1159/000367734] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
27 Cho YY, Yu SJ, Lee HW, Kim DY, Kang W, Paik YH, Sung PS, Bae SH, Park SC, Doh YS, Kim KM, Jang ES, Kim IH, Kim W, Kim YJ. Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. J Hepatocell Carcinoma 2021;8:613-23. [PMID: 34169044 DOI: 10.2147/JHC.S304439] [Reference Citation Analysis]
28 Tsurusaki M, Murakami T. Surgical and Locoregional Therapy of HCC: TACE. Liver Cancer 2015;4:165-75. [PMID: 26675172 DOI: 10.1159/000367739] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 8.2] [Reference Citation Analysis]
29 von Felden J, Schulze K, Krech T, Ewald F, Nashan B, Pantel K, Lohse AW, Riethdorf S, Wege H. Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. Oncotarget. 2017;8:89978-89987. [PMID: 29163804 DOI: 10.18632/oncotarget.21208] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
30 Peck-Radosavljevic M. Drug therapy for advanced-stage liver cancer. Liver Cancer 2014;3:125-31. [PMID: 24945003 DOI: 10.1159/000343868] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
31 Li C, Xu X. Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma. Cell Mol Life Sci 2019;76:4203-19. [PMID: 31300868 DOI: 10.1007/s00018-019-03215-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
32 Lyu N, Kong Y, Pan T, Mu L, Li S, Liu Y, Deng H, Li J, Shi M, Xu L, Guo R, Chen M, Wu P, Zhao M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. J Vasc Interv Radiol 2019;30:349-357.e2. [PMID: 30819477 DOI: 10.1016/j.jvir.2018.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
33 Lu XJ, Dong J, Ji LJ, Luo JH, Cao HM, Xiao LX, Zhou J, Ling CQ. Safety and efficacy of TACE and gamma knife on hepatocellular carcinoma with portal vein invasion. Gut. 2016;65:715-716. [PMID: 26268743 DOI: 10.1136/gutjnl-2015-310292] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
34 Zeng J, Wang C, Wang Y, Luo Z, Zhang Y, Luo X. Sorafenib plus partial splenic embolism for treatment of hepatocellular carcinoma Barcelona stage C combined with hypersplenism: a case series. J Int Med Res 2021;49:3000605211023351. [PMID: 34139869 DOI: 10.1177/03000605211023351] [Reference Citation Analysis]
35 Reig M, Gazzola A, Di Donato R, Bruix J. Systemic treatment. Best Practice & Research Clinical Gastroenterology 2014;28:921-35. [DOI: 10.1016/j.bpg.2014.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
36 Siu EH, Chan AW, Chong CC, Chan SL, Lo KW, Cheung ST. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Transl Gastroenterol Hepatol. 2018;3:89. [PMID: 30603725 DOI: 10.21037/tgh.2018.10.16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
37 Shen L, Xi M, Zhao L, Zhang X, Wang X, Huang Z, Chen Q, Zhang T, Shen J, Liu M, Huang J. Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib. Cancers (Basel) 2018;10:E516. [PMID: 30558224 DOI: 10.3390/cancers10120516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
38 Costentin CE, Ferrone CR, Arellano RS, Ganguli S, Hong TS, Zhu AX. Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. Liver Cancer 2017;6:360-74. [PMID: 29234639 DOI: 10.1159/000481315] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
39 Cheng S, Yang J, Shen F, Zhou W, Wang Y, Cong W, Yang GS, Cheng H, Hu H, Gao C, Guo J, Li A, Meng Y, Jiang X, Yang Y, Qian G, Luo M, Hu B, Man X, Zhang B, Su C, Zhou F, Li N, Shi J, Wang M, Zheng Y, Guo W, Sun J, Wang H, Lau WY, Wu MC. Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement. Oncotarget 2016;7:40816-29. [PMID: 27027235 DOI: 10.18632/oncotarget.8386] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
40 Knox JJ, Cleary SP, Dawson LA. Localized and Systemic Approaches to Treating Hepatocellular Carcinoma. JCO 2015;33:1835-44. [DOI: 10.1200/jco.2014.60.1153] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
41 Shao YY, Hsieh MS, Wang HY, Li YS, Lin H, Hsu HW, Huang CY, Hsu CH, Cheng AL. Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells. Oncotarget. 2017;8:86681-86692. [PMID: 29156827 DOI: 10.18632/oncotarget.21407] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
42 Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of HCC in special populations. J Hepatol 2021;74:931-43. [PMID: 33248171 DOI: 10.1016/j.jhep.2020.11.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
43 Kong W, Yuan H, Cai H, Wang W, Tang Y, Zhang X. Early treatment response to sorafenib for rabbit VX2 orthotic liver tumors: evaluation by quantitative contrast-enhanced ultrasound. Tumor Biol 2015;36:2593-9. [DOI: 10.1007/s13277-014-2877-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
44 Allaire M, Goumard C, Lim C, Le Cleach A, Wagner M, Scatton O. New frontiers in liver resection for hepatocellular carcinoma. JHEP Rep. 2020;2:100134. [PMID: 32695968 DOI: 10.1016/j.jhepr.2020.100134] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
45 Ogasawara S, Chiba T, Ooka Y, Suzuki E, Inoue M, Wakamatsu T, Tawada A, Yokosuka O. Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. PLoS One 2016;11:e0161303. [PMID: 27537374 DOI: 10.1371/journal.pone.0161303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
46 Sellers CM, Uhlig J, Ludwig JM, Pollak JS, Taddei TH, Stein SM, Lim JK, Kim HS. The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma. Cancer Med 2021;10:5395-404. [PMID: 34318618 DOI: 10.1002/cam4.3573] [Reference Citation Analysis]
47 Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer 2017;17:645. [PMID: 28899349 DOI: 10.1186/s12885-017-3545-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
48 Zhang XP, Wang K, Li N, Zhong CQ, Wei XB, Cheng YQ, Gao YZ, Wang H, Cheng SQ. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. BMC Cancer 2017;17:902. [PMID: 29282010 DOI: 10.1186/s12885-017-3895-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
49 Gopal S, Achenbach CJ, Yanik EL, Dittmer DP, Eron JJ, Engels EA. Moving forward in HIV-associated cancer. J Clin Oncol. 2014;32:876-880. [PMID: 24550416 DOI: 10.1200/jco.2013.53.1376] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 4.1] [Reference Citation Analysis]
50 Mao J, Wang D, Wang Z, Tian W, Li X, Duan J, Wang Y, Yang H, You L, Cheng Y, Bian J, Chen Z, Yang Y. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway. Cancer Lett 2016;380:134-43. [PMID: 27349166 DOI: 10.1016/j.canlet.2016.06.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
51 Golfieri R, Bilbao JI, Carpanese L, Cianni R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Cappelli A, Rodriguez M. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol. 2013;59:753-761. [PMID: 23707371 DOI: 10.1016/j.jhep.2013.05.025] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
52 Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu F, Liu L, Zhou J, Dou K, Yip CS, Yang X. Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data. Tumour Biol 2017;39:1010428317695030. [PMID: 28349781 DOI: 10.1177/1010428317695030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
53 Yoon JS, Sinn DH, Lee JH, Kim HY, Lee CH, Kim SW, Lee HY, Nam JY, Chang Y, Lee YB, Cho EJ, Yu SJ, Kim HC, Chung JW, Kim YJ, Yoon JH. Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. Cancers (Basel) 2019;11:E1721. [PMID: 31689972 DOI: 10.3390/cancers11111721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492-2502. [PMID: 28434648 DOI: 10.1016/s0140-6736(17)31046-2] [Cited by in Crossref: 1593] [Cited by in F6Publishing: 911] [Article Influence: 398.3] [Reference Citation Analysis]
55 Wörns MA, Galle PR. Sorafenib for the treatment of hepatocellular carcinoma. Hepat Oncol 2014;1:189-204. [PMID: 30190954 DOI: 10.2217/hep.13.20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
56 Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol. 2015;7:1184-1191. [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
57 Kudo M. Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial. Liver Cancer. 2018;7:225-234. [PMID: 30319982 DOI: 10.1159/000492535] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
58 Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358-380. [PMID: 28130846 DOI: 10.1002/hep.29086] [Cited by in Crossref: 1290] [Cited by in F6Publishing: 1082] [Article Influence: 430.0] [Reference Citation Analysis]
59 Ribeiro de Souza A, Reig M, Bruix J. Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opinion on Pharmacotherapy 2016;17:1923-36. [DOI: 10.1080/14656566.2016.1225722] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
60 Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, Lenis D, Stuart EA, Nonyane BA, Pekurovsky V, Tamrazi A, Gebauer B, Schlachter T, Pawlik TM, Geschwind JF. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol 2017;27:526-35. [PMID: 27277261 DOI: 10.1007/s00330-016-4445-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
61 Ikeda M, Okusaka T, Furuse J, Mitsunaga S, Ueno H, Yamaura H, Inaba Y, Takeuchi Y, Satake M, Arai Y. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2013;72:463-470. [PMID: 23812005 DOI: 10.1007/s00280-013-2222-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
62 Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev. 2018;68:16-24. [PMID: 29783126 DOI: 10.1016/j.ctrv.2018.05.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 22.7] [Reference Citation Analysis]
63 Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kawaratani H, Kitade M, Moriya K, Namisaki T, Yoshiji H. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer. 2018;142:1712-1722. [PMID: 29205334 DOI: 10.1002/ijc.31193] [Cited by in Crossref: 55] [Cited by in F6Publishing: 37] [Article Influence: 13.8] [Reference Citation Analysis]
64 Lee S, Lee M, Kim JB, Jo A, Cho EJ, Yu SJ, Lee JH, Yoon JH, Kim YJ. 17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling. Biochem Biophys Res Commun 2016;473:1247-54. [PMID: 27091428 DOI: 10.1016/j.bbrc.2016.04.049] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
65 Chang W, Lu S, Rau K, Huang C, Lee K. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients. The Kaohsiung Journal of Medical Sciences 2018;34:391-9. [DOI: 10.1016/j.kjms.2018.03.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
66 Wang K, Kievit FM, Sham JG, Jeon M, Stephen ZR, Bakthavatsalam A, Park JO, Zhang M. Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model. Small 2016;12:477-87. [PMID: 26641029 DOI: 10.1002/smll.201501985] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
67 Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M. Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology. 2014;86:63-71. [PMID: 24401634 DOI: 10.1159/000356573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
68 Blazquez AG, Fernandez-dolon M, Sanchez-vicente L, Maestre AD, Gomez-san Miguel AB, Alvarez M, Serrano MA, Jansen H, Efferth T, Marin JJ, Romero MR. Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis. Bioorganic & Medicinal Chemistry 2013;21:4432-41. [DOI: 10.1016/j.bmc.2013.04.059] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 6.6] [Reference Citation Analysis]
69 Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-radosavljevic M, Sieghart W. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. Journal of Hepatology 2014;61:1287-96. [DOI: 10.1016/j.jhep.2014.07.002] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 11.4] [Reference Citation Analysis]
70 Harris WP, Wong KM, Saha S, Dika IE, Abou-Alfa GK. Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers. Semin Oncol 2018;45:116-23. [PMID: 30348531 DOI: 10.1053/j.seminoncol.2018.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
71 Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, Paraná R, Mastai R, Strauss E, Guevara-Casallas LG, Daruich J, Gadano A, Parise ER, Uribe M, Aguilar-Olivos NE, Dagher L, Ferraz-Neto BH, Valdés-Sánchez M, Sánchez-Avila JF. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014;13 Suppl 1:S4-40. [PMID: 24998696 [PMID: 24998696 DOI: 10.1016/s1665-2681(19)30919-6] [Cited by in Crossref: 17] [Article Influence: 2.8] [Reference Citation Analysis]
72 Zou J, Zhu W, Meng H, Luo P, Zhang J. Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2019;13:271-9. [PMID: 30791765 DOI: 10.1080/17474124.2019.1570135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
73 Shiba S, Shibuya K, Okamoto M, Okazaki S, Komatsu S, Kubota Y, Nakano T, Ohno T. Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma. Radiat Oncol 2020;15:195. [PMID: 32795340 DOI: 10.1186/s13014-020-01634-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 97] [Article Influence: 19.7] [Reference Citation Analysis]
75 Lv WF, Liu KC, Lu D, Zhou CZ, Cheng DL, Xiao JK, Zhang XM, Zhang ZF. Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis. Cancer Manag Res 2018;10:4719-26. [PMID: 30410405 DOI: 10.2147/CMAR.S166527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
76 Cooke P, Sindhu KK, Lehrer EJ, Maron SZ, Rosenzweig KE, Buckstein M. Palliating Symptoms in Patients With Hepatocellular Carcinoma Involving the Inferior Vena Cava With External Beam Radiation Therapy. Cureus 2021;13:e14107. [PMID: 33927921 DOI: 10.7759/cureus.14107] [Reference Citation Analysis]
77 Yu JI, Park HC, Lim DH, Paik SW. Do Biliary Complications after Hypofractionated Radiation Therapy in Hepatocellular Carcinoma Matter? Cancer Res Treat. 2016;48:574-582. [PMID: 26194367 DOI: 10.4143/crt.2015.076] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
78 Serper M, Taddei TH, Mehta R, D'Addeo K, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Goldberg DS, Valderrama A, Kaplan DE; VOCAL Study Group. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology. 2017;152:1954-1964. [PMID: 28283421 DOI: 10.1053/j.gastro.2017.02.040] [Cited by in Crossref: 94] [Cited by in F6Publishing: 74] [Article Influence: 23.5] [Reference Citation Analysis]
79 Fukushima D, Imai S, Nishino N, Hamada K, Horikawa Y, Shiwa Y, Nishida S, Koyanagi R, Wada H, Sakuma H. A case of complete remission of advanced hepatocellular carcinoma with type III portal vein tumor thrombosis treated using transarterial chemoembolization with microspheres and radiation therapy. Clin J Gastroenterol 2020;13:847-54. [PMID: 32350739 DOI: 10.1007/s12328-020-01124-5] [Reference Citation Analysis]
80 Torrecilla S, Llovet JM. New molecular therapies for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2015;39 Suppl 1:S80-5. [PMID: 26206572 DOI: 10.1016/j.clinre.2015.06.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
81 Biolato M, Gallusi G, Iavarone M, Cabibbo G, Racco S, Santis AD, Corte CD, Maida M, Attili AF, Sangiovanni A, Cammà C, La Torre G, Gasbarrini A, Grieco A. Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Annals of Hepatology 2018;17:110-8. [DOI: 10.5604/01.3001.0010.7542] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
82 Ramaswami R, Pinato DJ, Kubota K, Ishizuka M, Arizumi T, Kudo M, Jang JW, Kim YW, Pirisi M, Allara E, Sharma R. Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. Med Oncol 2016;33:114. [PMID: 27601241 DOI: 10.1007/s12032-016-0827-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
83 Carrillo FJ, Mattos AA, Vianey AF, Vezozzo DC, Marinho F, Souto FJ, Cotrim HP, Coelho HS, Silva I, Garcia JH. Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. Arq Gastroenterol. 2015;52 Suppl 1:2-14. [PMID: 26959803 DOI: 10.1590/s0004-28032015000500001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
84 Wang E, Liu L, Xia D, Wang W, Bai W, Wang Q, Yuan J, Li X, Zhang L, Niu J, Yin Z, Xia J, Cai H, Fan D, Han G. Chemoembolization for Hepatocellular Carcinoma in Patients with Extrahepatic Spread: Prognostic Determinants and Appropriate Candidates. J Vasc Interv Radiol 2017;28:956-62. [PMID: 28420555 DOI: 10.1016/j.jvir.2017.02.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Sangro B. Chemoembolization and radioembolization. Best Practice & Research Clinical Gastroenterology 2014;28:909-19. [DOI: 10.1016/j.bpg.2014.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
86 Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624-1636. [PMID: 29107679 DOI: 10.1016/s1470-2045(17)30683-6] [Cited by in Crossref: 300] [Cited by in F6Publishing: 110] [Article Influence: 75.0] [Reference Citation Analysis]
87 Pereira RM, Ferreira-Silva GÁ, Pivatto M, Santos Lde Á, Bolzani Vda S, Chagas de Paula DA, Oliveira JC, Viegas Júnior C, Ionta M. Alkaloids derived from flowers of Senna spectabilis, (-)-cassine and (-)-spectaline, have antiproliferative activity on HepG2 cells for inducing cell cycle arrest in G1/S transition through ERK inactivation and downregulation of cyclin D1 expression. Toxicol In Vitro 2016;31:86-92. [PMID: 26616281 DOI: 10.1016/j.tiv.2015.11.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
88 Kim YH, Kim do Y. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know. Oncology. 2013;84 Suppl 1:34-39. [PMID: 23428856 DOI: 10.1159/000345887] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
89 Wang JC, Xia AL, Xu Y, Lu XJ. Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. J Cell Physiol. 2019;234:1062-1070. [PMID: 30256409 DOI: 10.1002/jcp.27324] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
90 Thomas MB, Garrett-Mayer E, Anis M, Anderton K, Bentz T, Edwards A, Brisendine A, Weiss G, Siegel AB, Bendell J, Baron A, Duddalwar V, El-Khoueiry A. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology 2018;94:329-39. [PMID: 29719302 DOI: 10.1159/000485384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
91 Kennedy A, Brown DB, Feilchenfeldt J, Marshall J, Wasan H, Fakih M, Gibbs P, Knuth A, Sangro B, Soulen MC, Pittari G, Sharma RA. Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. J Gastrointest Oncol 2017;8:1079-99. [PMID: 29299370 DOI: 10.21037/jgo.2017.09.10] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
92 Ferreira CPDC, Ribeiro MA, Szutan LA. Overall survival predictors in hepatocellular carcinoma patients treated with sorafenib. Rev Assoc Med Bras (1992) 2020;66:275-83. [PMID: 32520145 DOI: 10.1590/1806-9282.66.3.275] [Reference Citation Analysis]
93 Diniz PHC, Silva SDDC, Faria LC, Vidigal PVT, Ferrari TCA. Clinical and laboratory parameters as predictors of long-term outcome according to the etiology of underlying chronic liver disease in patients who underwent liver transplantation for hepatocellular carcinoma treatment. Clinics (Sao Paulo) 2020;75:e1529. [PMID: 32520221 DOI: 10.6061/clinics/2020/e1529] [Reference Citation Analysis]
94 Gu Y, Li X, Bi Y, Zheng Y, Wang J, Li X, Huang Z, Chen L, Huang Y, Huang Y. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging (Albany NY) 2020;12:784-807. [PMID: 31927532 DOI: 10.18632/aging.102656] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 21.0] [Reference Citation Analysis]
95 Kennedy AS, Sangro B. Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep. 2014;16:373. [PMID: 24488546 DOI: 10.1007/s11912-013-0373-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
96 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Reference Citation Analysis]
97 Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol. 2015;7:1041-1053. [PMID: 26052393 DOI: 10.4254/wjh.v7.i8.1041] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
98 Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, Sulpice L, Boudjema K, Mesbah M, Guillygomarc’h A. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40:1057-1068. [PMID: 23613103 DOI: 10.1007/s00259-013-2395-x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 89] [Article Influence: 14.5] [Reference Citation Analysis]
99 Thorley H, Porter K, Fleming C, Jones T, Kesten J, Marques E, Richards A, Savović J. Interventions for preventing or treating malnutrition in problem drinkers who are homeless or vulnerably housed: protocol for a systematic review. Syst Rev 2015;4:131. [PMID: 26424296 DOI: 10.1186/s13643-015-0114-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
100 Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol. 2017;67:999-1008. [PMID: 28687477 DOI: 10.1016/j.jhep.2017.06.026] [Cited by in Crossref: 234] [Cited by in F6Publishing: 209] [Article Influence: 58.5] [Reference Citation Analysis]
101 Lewandowski RJ, Andreoli JM, Hickey R, Kallini JR, Gabr A, Baker T, Kircher S, Salem R, Kulik L. Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib. J Vasc Interv Radiol 2016;27:1329-36. [PMID: 27266362 DOI: 10.1016/j.jvir.2016.03.043] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
102 Sekino Y, Okumura T, Fukumitsu N, Iizumi T, Numajiri H, Mizumoto M, Nakai K, Nonaka T, Ishikawa H, Sakurai H. Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. J Cancer Res Clin Oncol 2020;146:711-20. [PMID: 31776663 DOI: 10.1007/s00432-019-03096-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
103 Baheti AD, Dunham GM, Ingraham CR, Moshiri M, Lall C, Park JO, Li D, Katz DS, Madoff DC, Bhargava P. Clinical implications for imaging of vascular invasion in hepatocellular carcinoma. Abdom Radiol 2016;41:1800-10. [DOI: 10.1007/s00261-016-0763-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
104 Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol. 2017;52:494-503. [PMID: 27549242 DOI: 10.1007/s00535-016-1247-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
105 Han K, Kim JH, Ko GY, Gwon DI, Sung KB. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. World J Gastroenterol 2016;22:407-16. [PMID: 26755886 DOI: 10.3748/wjg.v22.i1.407] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
106 Ho MC, Hasegawa K, Chen XP, Nagano H, Lee YJ, Chau GY, Zhou J, Wang CC, Choi YR, Poon RT, Kokudo N. Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer 2016;5:245-56. [PMID: 27781197 DOI: 10.1159/000449336] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 6.6] [Reference Citation Analysis]
107 Keane FK, Hong TS, Zhu AX. Evolving Systemic Therapy in Hepatocellular Carcinoma: Current Management and Opportunities for Integration With Radiotherapy. Semin Radiat Oncol 2018;28:332-41. [PMID: 30309643 DOI: 10.1016/j.semradonc.2018.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
108 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 862] [Article Influence: 188.2] [Reference Citation Analysis]
109 Brunot A, Le Sourd S, Pracht M, Edeline J. Hepatocellular carcinoma in elderly patients: challenges and solutions. J Hepatocell Carcinoma. 2016;3:9-18. [PMID: 27574587 DOI: 10.2147/jhc.s101448] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 4.4] [Reference Citation Analysis]
110 Ding C, Zhang C, Zhang M, Chen YZ, Tan C, Tan Y, Jiang Y. Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2. Future Medicinal Chemistry 2014;6:1771-89. [DOI: 10.4155/fmc.14.112] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
111 Xia H, Dai X, Yu H, Zhou S, Fan Z, Wei G, Tang Q, Gong Q, Bi F. EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy. Cell Death Dis 2018;9:269. [PMID: 29449645 DOI: 10.1038/s41419-018-0302-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 14.7] [Reference Citation Analysis]
112 Costentin CE, Decaens T, Laurent A, Nault J, Paule B, Letoublon C, Luciani A, Calderaro J, Adam R, Bricault I, Amaddeo G, Cherqui D, Mallat A, Samuel D, Duvoux C, Ganne-carrié N, Roudot-thoraval F, Vibert E. Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis. Liver Int 2017;37:1869-76. [DOI: 10.1111/liv.13491] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
113 Cheng CC, Chao WT, Liao CC, Tseng YH, Lai YC, Lai YS, Hsu YH, Liu YH. Plectin deficiency in liver cancer cells promotes cell migration and sensitivity to sorafenib treatment. Cell Adh Migr 2018;12:19-27. [PMID: 28276928 DOI: 10.1080/19336918.2017.1288789] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
114 Waller LP, Deshpande V, Pyrsopoulos N. Hepatocellular carcinoma: A comprehensive review. World J Hepatol. 2015;7:2648-2663. [PMID: 26609342 DOI: 10.4254/wjh.v7.i26.2648] [Cited by in Crossref: 115] [Cited by in F6Publishing: 104] [Article Influence: 19.2] [Reference Citation Analysis]
115 Castelli G, Burra P, Giacomin A, Vitale A, Senzolo M, Cillo U, Farinati F. Sorafenib use in the transplant setting. Liver Transpl. 2014;20:1021-1028. [PMID: 24809799 DOI: 10.1002/lt.23911] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
116 Jiang W, Ji M. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. Semin Cancer Biol 2019;59:3-22. [PMID: 30943434 DOI: 10.1016/j.semcancer.2019.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
117 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
118 Shi Y, Mo X, Hong S, Li T, Chen B, Chen G. Studying the Role and Molecular Mechanisms of MAP4K3 in Sorafenib Resistance of Hepatocellular Carcinoma. Biomed Res Int 2020;2020:4965670. [PMID: 33204699 DOI: 10.1155/2020/4965670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
119 Sun JX, Shi J, Li N, Guo WX, Wu MC, Lau WY, Cheng SQ. Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma. Cancer Biol Med 2016;13:452-8. [PMID: 28154776 DOI: 10.20892/j.issn.2095-3941.2016.0059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
120 Gon H, Kido M, Tanaka M, Kinoshita H, Komatsu S, Tsugawa D, Awazu M, Toyama H, Matsumoto I, Itoh T, Fukumoto T. Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma. Surgery 2018;164:1014-22. [DOI: 10.1016/j.surg.2018.06.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
121 Jackson R, Psarelli EE, Berhane S, Khan H, Johnson P. Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials. J Clin Oncol. 2017;35:622-628. [PMID: 28045619 DOI: 10.1200/jco.2016.69.5197] [Cited by in Crossref: 69] [Cited by in F6Publishing: 42] [Article Influence: 17.3] [Reference Citation Analysis]
122 Sabbatini R, Ortega C, Procopio G, Masini C, Galligioni E, Porta C. Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. Future Oncol 2013;9:831-43. [PMID: 23718304 DOI: 10.2217/fon.13.58] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
123 Fung AS, Tam VC, Meyers DE, Sim HW, Knox JJ, Zaborska V, Davies J, Ko YJ, Batuyong E, Samawi H, Cheung WY, Lee-Ying R. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab. Cancer Med 2020;9:4640-7. [PMID: 32378799 DOI: 10.1002/cam4.3116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
124 Wakayama K, Kamiyama T, Yokoo H, Kakisaka T, Kamachi H, Tsuruga Y, Nakanishi K, Shimamura T, Todo S, Taketomi A. Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium. World J Surg Oncol. 2013;11:259. [PMID: 24093164 DOI: 10.1186/1477-7819-11-259] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
125 Park KH, Kim JH, Choe WH, Kwon SY, Yoo BC, Hwang JH, Park SW, Kim YJ, Park HS, Yu MH, Jeon HJ. Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients. Korean J Gastroenterol 2020;75:147-56. [PMID: 32209803 DOI: 10.4166/kjg.2020.75.3.147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Tseng CL, Lai WJ, Huang CJ, Huang YH, Su CW, Lee IC, Tseng HS, Li CP, Lee RC, Lin HC, Chao Y. The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment: A Cohort Study in Taiwan. Medicine (Baltimore) 2015;94:e1659. [PMID: 26632677 DOI: 10.1097/MD.0000000000001659] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
127 Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer 2021;10:181-223. [PMID: 34239808 DOI: 10.1159/000514174] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Marin JJG, Lozano E, Herraez E, Asensio M, Di Giacomo S, Romero MR, Briz O, Serrano MA, Efferth T, Macias RIR. Chemoresistance and chemosensitization in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1444-1453. [PMID: 28600147 DOI: 10.1016/j.bbadis.2017.06.005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 12.3] [Reference Citation Analysis]
129 Spreafico C, Maccauro M, Mazzaferro V, Chiesa C. The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). Eur J Nucl Med Mol Imaging 2014;41:634-8. [DOI: 10.1007/s00259-013-2674-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
130 Fu J, Zhang JY, Wang FS. Tamibarotene: a new hope for therapeutic efficacy in hepatocellular carcinoma patients. Hepatol Int 2014;8:1-3. [PMID: 26202399 DOI: 10.1007/s12072-013-9493-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
131 Pan T, Li XS, Xie QK, Wang JP, Li W, Wu PH, Zhao M. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus. Clin Radiol. 2014;69:e553-e561. [PMID: 25304928 DOI: 10.1016/j.crad.2014.09.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
132 Yu JI, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2016;22:6851-6863. [PMID: 27570422 DOI: 10.3748/wjg.v22.i30.6851] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
133 Wang Q, Xia D, Bai W, Wang E, Sun J, Huang M, Mu W, Yin G, Li H, Zhao H, Li J, Zhang C, Zhu X, Wu J, Gong W, Li Z, Lin Z, Pan X, Shi H, Shao G, Liu J, Yang S, Zheng Y, Xu J, Song J, Wang W, Wang Z, Zhang Y, Ding R, Zhang H, Yu H, Zheng L, Gu W, You N, Wang G, Zhang S, Feng L, Liu L, Zhang P, Li X, Chen J, Xu T, Zhou W, Zeng H, Huang W, Jiang W, Zhang W, Shao W, Li L, Niu J, Yuan J, Lv Y, Li K, Yin Z, Xia J, Fan D, Han G;  China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019;70:893-903. [PMID: 30660709 DOI: 10.1016/j.jhep.2019.01.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 25.0] [Reference Citation Analysis]
134 Liu M, Shi J, Mou T, Wang Y, Wu Z, Shen A. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol Hepatol. 2020;35:1277-1287. [PMID: 32052876 DOI: 10.1111/jgh.15010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
135 Gbolahan OB, Schacht MA, Beckley EW, LaRoche TP, O'Neil BH, Pyko M. Locoregional and systemic therapy for hepatocellular carcinoma. J Gastrointest Oncol. 2017;8:215-228. [PMID: 28480062 DOI: 10.21037/jgo.2017.03.13] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 9.5] [Reference Citation Analysis]
136 Di Costanzo GG, Casadei Gardini A, Marisi G, Foschi FG, Scartozzi M, Granata R, Faloppi L, Cascinu S, Silvestris N, Brunetti O, Palmieri VO, Ercolani G, Tortora R. Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Targ Oncol 2017;12:795-803. [DOI: 10.1007/s11523-017-0522-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
137 Bouattour M, Mehta N, He AR, Cohen EI, Nault JC. Systemic Treatment for Advanced Hepatocellular Carcinoma. Liver Cancer. 2019;8:341-358. [PMID: 31768344 DOI: 10.1159/000496439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 16.5] [Reference Citation Analysis]
138 Zhou Y, Li Y, Zhou T, Zheng J, Li S, Li HB. Dietary Natural Products for Prevention and Treatment of Liver Cancer. Nutrients. 2016;8:156. [PMID: 26978396 DOI: 10.3390/nu8030156] [Cited by in Crossref: 99] [Cited by in F6Publishing: 84] [Article Influence: 19.8] [Reference Citation Analysis]
139 Kimura O, Kondo Y, Kogure T, Kakazu E, Ninomiya M, Iwata T, Morosawa T, Shimosegawa T. Expression of EpCAM increases in the hepatitis B related and the treatment-resistant hepatocellular carcinoma. Biomed Res Int. 2014;2014:172913. [PMID: 24696843 DOI: 10.1155/2014/172913] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
140 Li K, Wang HT, He YK, Guo T. New idea for treatment strategies for Barcelona Clinic Liver Cancer stages based on a network meta-analysis. Medicine (Baltimore) 2017;96:e6950. [PMID: 28514316 DOI: 10.1097/MD.0000000000006950] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
141 Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study. Mol Clin Oncol 2017;7:1013-20. [PMID: 29285366 DOI: 10.3892/mco.2017.1442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
142 Fernandes M, Jamme P, Cortot AB, Kherrouche Z, Tulasne D. When the MET receptor kicks in to resist targeted therapies. Oncogene 2021;40:4061-78. [PMID: 34031544 DOI: 10.1038/s41388-021-01835-0] [Reference Citation Analysis]
143 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis. J Cancer 2017;8:378-87. [PMID: 28261338 DOI: 10.7150/jca.16786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
144 Farinha D, Migawa M, Sarmento-Ribeiro A, Faneca H. A Combined Antitumor Strategy Mediated by a New Targeted Nanosystem to Hepatocellular Carcinoma. Int J Nanomedicine 2021;16:3385-405. [PMID: 34040370 DOI: 10.2147/IJN.S302288] [Reference Citation Analysis]
145 Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol. 2015;21:3462-3471. [PMID: 25834310 DOI: 10.3748/wjg.v21.i12.3462] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
146 Huang XY, Huang ZL, Zhang PB, Huang XY, Huang J, Wang HC, Xu B, Zhou J, Tang ZY. CircRNA-100338 Is Associated With mTOR Signaling Pathway and Poor Prognosis in Hepatocellular Carcinoma. Front Oncol 2019;9:392. [PMID: 31157168 DOI: 10.3389/fonc.2019.00392] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
147 Martínez-Cardona C, Lozano-Ruiz B, Bachiller V, Peiró G, Algaba-Chueca F, Gómez-Hurtado I, Such J, Zapater P, Francés R, González-Navajas JM. AIM2 deficiency reduces the development of hepatocellular carcinoma in mice. Int J Cancer 2018;143:2997-3007. [PMID: 30133699 DOI: 10.1002/ijc.31827] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
148 Shi L, Yan P, Liang Y, Sun Y, Shen J, Zhou S, Lin H, Liang X, Cai X. Circular RNA expression is suppressed by androgen receptor (AR)-regulated adenosine deaminase that acts on RNA (ADAR1) in human hepatocellular carcinoma. Cell Death Dis 2017;8:e3171. [PMID: 29144509 DOI: 10.1038/cddis.2017.556] [Cited by in Crossref: 63] [Cited by in F6Publishing: 64] [Article Influence: 15.8] [Reference Citation Analysis]
149 Sánchez AIP, Roces LV, García IZ, López EL, Hernandez MAC, Parejo MIB, Peña-Díaz J. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncol Lett 2018;15:8863-70. [PMID: 29805623 DOI: 10.3892/ol.2018.8400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
150 Li Y, Wei J, Wei Y, Cheng L, Guo B, Meng F, Li F, Zhong Z. Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma. Biomacromolecules 2020;21:716-24. [DOI: 10.1021/acs.biomac.9b01419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
151 Karin M. New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. Precis Clin Med. 2018;1:21-28. [PMID: 30687560 DOI: 10.1093/pcmedi/pby005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
152 Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial. World J Hepatol 2016;8:957-60. [PMID: 27621761 DOI: 10.4254/wjh.v8.i23.957] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
153 Kawaoka T, Aikata H, Hyogo H, Morio R, Morio K, Hatooka M, Fukuhara T, Kobayashi T, Naeshiro N, Miyaki D. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. J Dig Dis. 2015;16:505-512. [PMID: 26121102 DOI: 10.1111/1751-2980.12267] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
154 Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019;16:617-630. [PMID: 31371809 DOI: 10.1038/s41575-019-0179-x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 28.5] [Reference Citation Analysis]
155 Kolamunnage-Dona R, Berhane S, Potts H, Williams EH, Tanner J, Janowitz T, Hoare M, Johnson P. Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. J Hepatol 2021:S0168-8278(21)00350-0. [PMID: 34052255 DOI: 10.1016/j.jhep.2021.05.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Kaneko S, Ikeda K, Matsuzaki Y, Furuse J, Minami H, Okayama Y, Sunaya T, Ito Y, Inuyama L, Okita K. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. J Gastroenterol 2016;51:1011-21. [PMID: 26931117 DOI: 10.1007/s00535-016-1173-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
157 Kimura O, Kondo Y, Shimosegawa T. PPAR Could Contribute to the Pathogenesis of Hepatocellular Carcinoma. PPAR Res. 2012;2012:574180. [PMID: 23316217 DOI: 10.1155/2012/574180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
158 Ong HT, Federspiel MJ, Guo CM, Ooi LL, Russell SJ, Peng KW, Hui KM. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J Hepatol 2013;59:999-1006. [PMID: 23867315 DOI: 10.1016/j.jhep.2013.07.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
159 Mao J, Yang H, Cui T, Pan P, Kabir N, Chen D, Ma J, Chen X, Chen Y, Yang Y. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT. Eur J Pharmacol 2018;832:39-49. [PMID: 29782854 DOI: 10.1016/j.ejphar.2018.05.027] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
160 Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2019;1873:188314. [PMID: 31682895 DOI: 10.1016/j.bbcan.2019.188314] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 30.0] [Reference Citation Analysis]
161 Zhou TY, Chen SQ, Wang HL, Weng SM, Zhou GH, Zhang YL, Nie CH, Zhu TY, Wang BQ, Yu ZN, Jing L, Chen F, Sun JH. Safety and efficacy of drug-eluting bead transarterial chemoembolization with CalliSpheres® microsphere for hepatocellular carcinoma with portal vein tumor thrombus: a preliminary study. J Cancer 2021;12:4522-9. [PMID: 34149916 DOI: 10.7150/jca.54650] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Liu Y, Sun L, Gao F, Yang X, Li Y, Zhang Q, Zhu B, Niu S, Huang Y, Hu Y, Feng Y, Jiang Y, Wang X. A new scoring model predicting macroscopic vascular invasion of early-intermediate hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e13536. [PMID: 30544459 DOI: 10.1097/MD.0000000000013536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
163 Escudier B, Worden F, Kudo M. Sorafenib: key lessons from over 10 years of experience. Expert Rev Anticancer Ther. 2019;19:177-189. [PMID: 30575405 DOI: 10.1080/14737140.2019.1559058] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
164 Wang Y, Gou Q, Xu R, Chen X, Zhou Z. Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study. Onco Targets Ther. 2018;11:3407-3413. [PMID: 29928132 DOI: 10.2147/ott.s161023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
165 Kwee SA, Wong LL, Sato MM, Acoba JD, Rho YS, Srivastava A, Landsittel DP. Transarterial Radioembolization for Hepatocellular Carcinoma with Major Vascular Invasion: A Nationwide Propensity Score-Matched Analysis with Target Trial Emulation. J Vasc Interv Radiol 2021;32:1258-1266.e6. [PMID: 34242775 DOI: 10.1016/j.jvir.2021.07.001] [Reference Citation Analysis]
166 Cappelli A, Cucchetti A, Cabibbo G, Mosconi C, Maida M, Attardo S, Pettinari I, Pinna AD, Golfieri R. Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Liver Int. 2016;36:729-736. [PMID: 26604044 DOI: 10.1111/liv.13029] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
167 Yoo GS, Yu JI, Park HC. Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives. World J Gastroenterol 2018;24:3090-100. [PMID: 30065555 DOI: 10.3748/wjg.v24.i28.3090] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 14] [Article Influence: 7.3] [Reference Citation Analysis]
168 Labeur TA, Berhane S, Edeline J, Blanc JF, Bettinger D, Meyer T, Van Vugt JLA, Ten Cate DWG, De Man RA, Eskens FALM, Cucchetti A, Bonnett LJ, Van Delden OM, Klümpen HJ, Takkenberg RB, Johnson PJ. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. Liver Int 2020;40:215-28. [PMID: 31579990 DOI: 10.1111/liv.14270] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
169 Huang WY, Tsai CL, Que JY, Lo CH, Lin YJ, Dai YH, Yang JF, Shen PC, Lee MH, Cheng JC. Development and Validation of a Nomogram for Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy. Liver Cancer 2020;9:326-37. [PMID: 32647634 DOI: 10.1159/000505693] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
170 Raoul JL, Gilabert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer 2014;3:119-24. [PMID: 24945002 DOI: 10.1159/000343867] [Cited by in Crossref: 39] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
171 Sun W, Cabrera R. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies. J Gastrointest Cancer 2018;49:107-15. [PMID: 29453759 DOI: 10.1007/s12029-018-0065-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
172 Lai Y, Feng B, Abudoureyimu M, Zhi Y, Zhou H, Wang T, Chu X, Chen P, Wang R. Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma. Front Oncol 2019;9:1156. [PMID: 31750247 DOI: 10.3389/fonc.2019.01156] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
173 Taketomi A. Clinical trials of antiangiogenic therapy for hepatocellular carcinoma. Int J Clin Oncol. 2016;21:213-218. [PMID: 26899258 DOI: 10.1007/s10147-016-0966-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
174 Venerito M, Pech M, Canbay A, Donghia R, Guerra V, Chatellier G, Pereira H, Gandhi M, Malfertheiner P, Chow PKH, Vilgrain V, Ricke J, Leandro G. NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with 90Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma. J Nucl Med 2020;61:1736-42. [PMID: 32358087 DOI: 10.2967/jnumed.120.242933] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
175 Medavaram S, Zhang Y. Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol. 2018;7:17. [PMID: 30087805 DOI: 10.1186/s40164-018-0109-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 14.7] [Reference Citation Analysis]
176 Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. Pharmacol Ther 2018;181:49-75. [PMID: 28723416 DOI: 10.1016/j.pharmthera.2017.07.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
177 Stieb S, Riesterer O, Brüssow C, Pestalozzi B, Guckenberger M, Weiler S. Radiation recall dermatitis induced by sorafenib: A case study and review of the literature. Strahlenther Onkol 2016;192:342-8. [DOI: 10.1007/s00066-016-0950-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
178 Abou-alfa GK, Jarnagin W, El Dika I, D'angelica M, Lowery M, Brown K, Ludwig E, Kemeny N, Covey A, Crane CH, Harding J, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1314-1341.e11. [DOI: 10.1016/b978-0-323-47674-4.00077-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
179 Rana N, Ju AW, Bazylewicz M, Kallakury B, He AR, Unger KR, Lee JS. Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib. Front Oncol. 2013;3:323. [PMID: 24416722 DOI: 10.3389/fonc.2013.00323] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
180 Han Y, Zhi WH, Xu F, Zhang CB, Huang XQ, Luo JF. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. World J Gastroenterol 2021;27:2415-33. [PMID: 34040331 DOI: 10.3748/wjg.v27.i19.2415] [Reference Citation Analysis]
181 Zhang W. Sorafenib in adjuvant setting: call for precise and personalized therapy. Transl Gastroenterol Hepatol 2016;1:13. [PMID: 28138580 DOI: 10.21037/tgh.2016.03.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
182 Klingenberg M, Matsuda A, Diederichs S, Patel T. Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. J Hepatol. 2017;67:603-618. [PMID: 28438689 DOI: 10.1016/j.jhep.2017.04.009] [Cited by in Crossref: 178] [Cited by in F6Publishing: 176] [Article Influence: 44.5] [Reference Citation Analysis]
183 Hatooka M, Kawaoka T, Aikata H, Inagaki Y, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Awai K, Masaki K, Waki K, Kohno H, Kohno H, Moriya T, Nagaoki Y, Tamura T, Amano H, Katamura Y, Chayama K. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. BMC Cancer 2018;18:633. [PMID: 29866075 DOI: 10.1186/s12885-018-4519-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
184 Zhou L, Li J, Ai DL, Fu JL, Peng XM, Zhang LZ, Wang JY, Zhao Y, Yang B, Yu Q. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma. Jpn J Clin Oncol. 2014;44:711-717. [PMID: 24855686 DOI: 10.1093/jjco/hyu068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
185 Garin E, Rolland Y, Edeline J, Icard N, Lenoir L, Laffont S, Mesbah H, Breton M, Sulpice L, Boudjema K, Rohou T, Raoul JL, Clement B, Boucher E. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J Nucl Med. 2015;56:339-346. [PMID: 25678490 DOI: 10.2967/jnumed.114.145177] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 12.2] [Reference Citation Analysis]
186 Elsegood CL, Tirnitz-Parker JE, Olynyk JK, Yeoh GC. Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma. Clin Transl Immunology. 2017;6:e161. [PMID: 29326816 DOI: 10.1038/cti.2017.47] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
187 Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, Kudo M, Iijima H, Genda T, Tateishi R, Torimura T, Igaki H, Kobayashi S, Sakurai H, Murakami T, Watadani T, Matsuyama Y. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49:1109-1113. [PMID: 31336394 DOI: 10.1111/hepr.13411] [Cited by in Crossref: 111] [Cited by in F6Publishing: 80] [Article Influence: 55.5] [Reference Citation Analysis]
188 Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis. Hepatol Commun 2020;4:1218-28. [PMID: 32766480 DOI: 10.1002/hep4.1535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
189 Park J, Cho J, Lim JH, Lee MH, Kim J. Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis. Target Oncol. 2019;14:395-403. [PMID: 31290003 DOI: 10.1007/s11523-019-00651-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
190 Harding JJ, Abou-Alfa GK. Treating advanced hepatocellular carcinoma: How to get out of first gear. Cancer. 2014;120:3122-3130. [PMID: 24898783 DOI: 10.1002/cncr.28850] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
191 Chen S, Peng Z, Wei M, Liu W, Dai Z, Wang H, Mei J, Cheong M, Zhang H, Kuang M. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis. BMC Cancer 2018;18:392. [PMID: 29621988 DOI: 10.1186/s12885-018-4308-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
192 Zeng J, Lv L, Mei Z. Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology 2016;40:688-97. [DOI: 10.1016/j.clinre.2016.04.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
193 Pan T, Xie Q, Lv N, Li X, Mu L, Wu P, Zhao M. Percutaneous CT-guided Radiofrequency Ablation for Lymph Node Oligometastases from Hepatocellular Carcinoma: A Propensity Score–matching Analysis. Radiology 2017;282:259-70. [DOI: 10.1148/radiol.2016151807] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
194 Facciorusso A, Bargellini I, Cela M, Cincione I, Sacco R. Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. Cancers (Basel) 2020;12:E897. [PMID: 32272656 DOI: 10.3390/cancers12040897] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
195 Kuzuya T, Ishigami M, Ishizu Y, Honda T, Hayashi K, Katano Y, Hirooka Y, Ishikawa T, Nakano I, Goto H. Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma. PLoS One. 2015;10:e0138776. [PMID: 26421430 DOI: 10.1371/journal.pone.0138776] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
196 Lamarca A, Abdel-rahman O, Salu I, Mcnamara MG, Valle JW, Hubner RA. Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. Clin Transl Oncol 2017;19:364-72. [DOI: 10.1007/s12094-016-1537-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
197 Clark T, Maximin S, Meier J, Pokharel S, Bhargava P. Hepatocellular Carcinoma: Review of Epidemiology, Screening, Imaging Diagnosis, Response Assessment, and Treatment. Curr Probl Diagn Radiol. 2015;44:479-486. [PMID: 25979220 DOI: 10.1067/j.cpradiol.2015.04.004] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 13.3] [Reference Citation Analysis]
198 Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. [PMID: 24159579 DOI: 10.1159/000343828] [Cited by in Crossref: 169] [Cited by in F6Publishing: 153] [Article Influence: 24.1] [Reference Citation Analysis]
199 Jun CH, Yoon JH, Cho E, Shin SS, Cho SB, Kim HJ, Park CH, Kim HS, Choi SK, Rew JS. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment. Medicine (Baltimore) 2017;96:e6745. [PMID: 28445298 DOI: 10.1097/MD.0000000000006745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
200 Lee SK, Jang JW, Nam H, Sung PS, Kim HY, Kwon JH, Lee SW, Song DS, Kim CW, Song MJ, Choi HJ, You YK, Bae SH, Choi JY, Yoon SK. Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation. Hepatol Int 2021;15:137-45. [PMID: 33496932 DOI: 10.1007/s12072-020-10131-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Personeni N, Rimassa L, Giordano L, Santoro A. Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater! J Clin Oncol 2017;35:2213-4. [PMID: 28471708 DOI: 10.1200/JCO.2017.72.7776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
202 Garin E, Rolland Y, Pracht M, Le Sourd S, Laffont S, Mesbah H, Haumont LA, Lenoir L, Rohou T, Brun V, Edeline J. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90 Y-loaded glass microsphere radioembolization. Liver Int 2017;37:101-10. [PMID: 27514012 DOI: 10.1111/liv.13220] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 7.6] [Reference Citation Analysis]
203 Lee SW, Tung CF, Peng YC, Lien HC, Chang CS. Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population. J Dig Dis 2020;21:462-7. [PMID: 32472590 DOI: 10.1111/1751-2980.12911] [Reference Citation Analysis]
204 Li H, Wang J, Liu H, Lan T, Xu L, Wang G, Yuan K, Wu H. Existence of intratumoral tertiary lymphoid structures is associated with immune cells infiltration and predicts better prognosis in early-stage hepatocellular carcinoma. Aging (Albany NY). 2020;12:3451-3472. [PMID: 32087064 DOI: 10.18632/aging.102821] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
205 Al-Rajabi R, Patel S, Ketchum NS, Jaime NA, Lu TW, Pollock BH, Mahalingam D. Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction. J Gastrointest Oncol. 2015;6:259-267. [PMID: 26029452 DOI: 10.3978/j.issn.2078-6891.2015.005] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
206 Gutierrez JA, Gish RG. Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. Transl Cancer Res 2013;2:460-71. [PMID: 26504748 DOI: 10.3978/j.issn.2218-676X.2013.10.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
207 Zakaria N, Mahdzir MA, Yusoff M, Mohd Arshad N, Awang K, Nagoor NH. Cytotoxic Effects of Pinnatane A Extracted from Walsura pinnata (Meliaceae) on Human Liver Cancer Cells. Molecules 2018;23:E2733. [PMID: 30360475 DOI: 10.3390/molecules23112733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
208 Yuan BH, Yuan WP, Li RH, Xiang BD, Gong WF, Li LQ, Zhong JH. Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma. Tumour Biol. 2016;37:2435-2441. [PMID: 26383523 DOI: 10.1007/s13277-015-4091-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
209 Cheung TT, Poon RT, Jenkins CR, Chu FS, Chok KS, Chan AC, Tsang SH, Dai WC, Yau TC, Chan SC. Survival analysis of high-intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas. Liver Int. 2014;34:e136-e143. [PMID: 24451026 DOI: 10.1111/liv.12474] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
210 Chiu CM, Huang SY, Chang SF, Liao KF, Chiu SC. Synergistic antitumor effects of tanshinone IIA and sorafenib or its derivative SC-1 in hepatocellular carcinoma cells. Onco Targets Ther 2018;11:1777-85. [PMID: 29636623 DOI: 10.2147/OTT.S161534] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
211 Xiao H, Li JL, Chen SL, Tang MM, Zhou Q, Wu TF, Li X, Peng ZW, Feng ST, Peng S, Kuang M. A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection. Front Oncol 2021;11:569515. [PMID: 33718130 DOI: 10.3389/fonc.2021.569515] [Reference Citation Analysis]
212 Aydin C, Yilmaz S. Is Macroscopic Portal Vein Tumor Thrombosis of HCC Really an Exclusion for Liver Transplantation? J Gastrointest Cancer 2020;51:1137-40. [PMID: 32833219 DOI: 10.1007/s12029-020-00488-8] [Reference Citation Analysis]
213 Regan-Fendt K, Li D, Reyes R, Yu L, Wani NA, Hu P, Jacob ST, Ghoshal K, Payne PRO, Motiwala T. Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2730. [PMID: 32977582 DOI: 10.3390/cancers12102730] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
214 Moriguchi M, Aramaki T, Nishiofuku H, Sato R, Asakura K, Yamaguchi K, Tanaka T, Endo M, Itoh Y. Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis. Liver Cancer 2017;6:275-86. [PMID: 29234631 DOI: 10.1159/000473887] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
215 Reynolds AR, Furlan A, Fetzer DT, Sasatomi E, Borhani AA, Heller MT, Tublin ME. Infiltrative Hepatocellular Carcinoma: What Radiologists Need to Know. RadioGraphics 2015;35:371-86. [DOI: 10.1148/rg.352140114] [Cited by in Crossref: 54] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
216 Song P, Hai Y, Ma W, Zhao L, Wang X, Xie Q, Li Y, Wu Z, Li Y, Li H. Arsenic trioxide combined with transarterial chemoembolization for unresectable primary hepatic carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e0613. [PMID: 29718867 DOI: 10.1097/MD.0000000000010613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
217 Abdel-Rahman O, Lamarca A. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. Expert Rev Gastroenterol Hepatol. 2017;11:75-83. [PMID: 27882800 DOI: 10.1080/17474124.2017.1264874] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
218 Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, Wang CK, Ikeda M, Chan SL, Choo SP, Miyayama S, Cheng AL. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 2020;9:245-60. [PMID: 32647629 DOI: 10.1159/000507370] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 25.0] [Reference Citation Analysis]
219 Krutsenko Y, Singhi AD, Monga SP. β-Catenin Activation in Hepatocellular Cancer: Implications in Biology and Therapy. Cancers (Basel) 2021;13:1830. [PMID: 33921282 DOI: 10.3390/cancers13081830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Toso C, Mentha G, Majno P. Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence. J Hepatol. 2013;59:3-5. [PMID: 23567081 DOI: 10.1016/j.jhep.2013.03.029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
221 Lu J, Zhang X, Zhong B, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng S, Teng G. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019;4:721-30. [DOI: 10.1016/s2468-1253(19)30178-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
222 Sohn W, Paik YH, Cho JY, Lim HY, Ahn JM, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. J Hepatol. 2015;62:1112-1121. [PMID: 25514557 DOI: 10.1016/j.jhep.2014.12.009] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
223 Cheng S, Chen M, Cai J; National Research Cooperative Group for Diagnosis and Treatment of Hepatocellular Carcinoma with Tumor Thrombus. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. Oncotarget. 2017;8:8867-8876. [PMID: 27780939 DOI: 10.18632/oncotarget.12817] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
224 Ma Y, Zhang C, Zhang B, Yu H, Yu Q. circRNA of AR-suppressed PABPC1 91 bp enhances the cytotoxicity of natural killer cells against hepatocellular carcinoma via upregulating UL16 binding protein 1. Oncol Lett 2019;17:388-97. [PMID: 30655779 DOI: 10.3892/ol.2018.9606] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
225 Sano S, Nakata S, Wada S, Kuroiwa M, Sakai H, Kusama K, Machida T, Nishio A, Ito I, Sodeyama H. Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report. World J Surg Oncol 2019;17:229. [PMID: 31878937 DOI: 10.1186/s12957-019-1772-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
226 Kim EH, Kim MS, Furusawa Y, Uzawa A, Han S, Jung WG, Sai S. Metformin enhances the radiosensitivity of human liver cancer cells to γ-rays and carbon ion beams. Oncotarget 2016;7:80568-78. [PMID: 27802188 DOI: 10.18632/oncotarget.12966] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
227 Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiotherapy and Oncology 2018;129:112-22. [DOI: 10.1016/j.radonc.2017.11.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 11.3] [Reference Citation Analysis]
228 Umezaki N, Nakagawa S, Yamashita YI, Kitano Y, Arima K, Miyata T, Hiyoshi Y, Okabe H, Nitta H, Hayashi H, Imai K, Chikamoto A, Baba H. Lysyl oxidase induces epithelial-mesenchymal transition and predicts intrahepatic metastasis of hepatocellular carcinoma. Cancer Sci 2019;110:2033-43. [PMID: 30919528 DOI: 10.1111/cas.14010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
229 Giannini EG, Moscatelli A, Pellegatta G, Vitale A, Farinati F, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Baroni GS, Virdone R, Masotto A, Trevisani F; Italian Liver Cancer (ITA. LI.CA) Group; Italian Liver Cancer ITA LI CA Group. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. Am J Gastroenterol. 2016;111:70-77. [PMID: 26729544 DOI: 10.1038/ajg.2015.389] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
230 Yeh ML, Huang CF, Huang CI, Hsieh MY, Hou NJ, Lin IH, Liang PC, Tsai YS, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. Kaohsiung J Med Sci 2019;35:624-32. [PMID: 31254328 DOI: 10.1002/kjm2.12105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
231 Atkin C, Earwaker P, Pallan A, Shetty S, Punia P, Ma YT. Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature. BMC Gastroenterol 2017;17:30. [PMID: 28193171 DOI: 10.1186/s12876-017-0585-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
232 von Felden J, Schulze K, Gil-Ibanez I, Werner T, Wege H. First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation. Diagnostics (Basel) 2016;6:E44. [PMID: 27916795 DOI: 10.3390/diagnostics6040044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
233 Brandi G, De Lorenzo S, Di Girolamo S, Bellentani S, Saccoccio G, Biasco G. Fulminant Hepatitis in a Patient with Hepatocellular Carcinoma Related to Nonalcoholic Steatohepatitis Treated with Sorafenib. Tumori 2015;101:e46-8. [DOI: 10.5301/tj.5000247] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
234 Cheng CC, Chao WT, Liao CC, Shih JH, Lai YS, Hsu YH, Liu YH. The Roles Of Angiogenesis And Cancer Stem Cells In Sorafenib Drug Resistance In Hepatocellular Carcinoma. Onco Targets Ther 2019;12:8217-27. [PMID: 31632072 DOI: 10.2147/OTT.S217468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
235 Lobo L, Yakoub D, Picado O, Ripat C, Pendola F, Sharma R, ElTawil R, Kwon D, Venkat S, Portelance L, Yechieli R. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol. 2016;39:1580-1588. [PMID: 27586657 DOI: 10.1007/s00270-016-1426-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
236 Li SH, Wang QX, Sun P, Li Q, Yang ZY, Shi M, Wei W, Guo RP. Surgical Strategy for Hepatocellular Carcinoma Patients with Portal/Hepatic Vein Tumor Thrombosis. PLoS One. 2015;10:e0130021. [PMID: 26076461 DOI: 10.1371/journal.pone.0130021] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
237 Li W, Wang Y, Kellner DB, Zhao L, Xu L, Gao Q. Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocelluar carcinoma. Oncol Lett. 2016;12:707-714. [PMID: 27347204 DOI: 10.3892/ol.2016.4629] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
238 Kasai Y, Hatano E, Seo S, Taura K, Yasuchika K, Okajima H, Kaido T, Uemoto S. Proposal of selection criteria for operative resection of hepatocellular carcinoma with inferior vena cava tumor thrombus incorporating hepatic arterial infusion chemotherapy. Surgery. 2017;162:742-751. [PMID: 28705491 DOI: 10.1016/j.surg.2017.05.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
239 Ouyang G, Pan G, Xu H, Wu Y, Liu Z, Lu W, Yi B, Chen X. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2020;54:675-81. [PMID: 32569032 DOI: 10.1097/MCG.0000000000001384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
240 Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, Morosi C, Lanocita R, Romito R, Chiesa C, Maccauro M, Marchianò A, Mazzaferro V. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol 2018;68:724-32. [PMID: 29331342 DOI: 10.1016/j.jhep.2017.12.026] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 17.7] [Reference Citation Analysis]
241 Vaira V, Roncalli M, Carnaghi C, Faversani A, Maggioni M, Augello C, Rimassa L, Pressiani T, Spagnuolo G, Di Tommaso L. MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. Liver Int. 2015;35:1077-1086. [PMID: 25040368 DOI: 10.1111/liv.12636] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.9] [Reference Citation Analysis]
242 Kim DK, Lee SW, Nam HS, Jeon DS, Park NR, Nam YH, Lee SK, Baek YH, Han SY, Lee SW. A Case of Sorafenib-induced DRESS Syndrome in Hepatocelluar Carcinoma. Korean J Gastroenterol 2016;67:337-40. [PMID: 27312836 DOI: 10.4166/kjg.2016.67.6.337] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
243 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
244 Ma KW, Chan ACY, Chok KSH, She WH, Cheung TT, Dai WC, Fung JYY, Lo CM. Liver transplantation: would it be the best and last chance of cure for hepatocellular carcinoma with major venous invasion? Hepatobiliary Surg Nutr 2021;10:308-14. [PMID: 34159158 DOI: 10.21037/hbsn.2020.03.09] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Zhu J, Yin T, Xu Y, Lu XJ. Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. J Cell Physiol. 2019;234:12122-12132. [PMID: 30644100 DOI: 10.1002/jcp.28048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
246 Edeline J, Crouzet L, Campillo-gimenez B, Rolland Y, Pracht M, Guillygomarc’h A, Boudjema K, Lenoir L, Adhoute X, Rohou T, Boucher E, Clément B, Blanc J, Garin E. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging 2016;43:635-43. [DOI: 10.1007/s00259-015-3210-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 8.7] [Reference Citation Analysis]
247 Chow PK, Poon DY, Khin MW, Singh H, Han HS, Goh AS, Choo SP, Lai HK, Lo RH, Tay KH, Lim TG, Gandhi M, Tan SB, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group. Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma. PLoS One 2014;9:e90909. [PMID: 24614178 DOI: 10.1371/journal.pone.0090909] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
248 Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol 2017;8:387-404. [PMID: 28736627 DOI: 10.21037/jgo.2017.01.04] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
249 Miyahara K, Nouso K, Yamamoto K. Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World J Gastroenterol. 2014;20:4151-4159. [PMID: 24764653 DOI: 10.3748/wjg.v20.i15.4151] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
250 Oikonomopoulos G, Aravind P, Sarker D. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma? Future Oncology 2016;12:465-76. [DOI: 10.2217/fon.15.341] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
251 Ye SL, Yang J, Bie P, Zhang S, Chen X, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Lv Z. Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study. BMC Cancer 2018;18:247. [PMID: 29499662 DOI: 10.1186/s12885-018-4144-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
252 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
253 Díaz-Rodríguez E, El-Mallah AM, Sanz E, Pandiella A. Antitumoral effect of Ocoxin in hepatocellular carcinoma. Oncol Lett 2017;14:1950-8. [PMID: 28781639 DOI: 10.3892/ol.2017.6440] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
254 Labeur TA, Takkenberg RB, Klümpen HJ, van Delden OM. Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2019;42:230-8. [PMID: 30488302 DOI: 10.1007/s00270-018-2118-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
255 Otsuka T, Nakashita S, Yanagita K, Ario K, Kawasoe H, Kawazoe S, Eguchi Y, Mizuta T. Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Diseases 2015;3:68-77. [PMID: 28943609 DOI: 10.3390/diseases3020068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
256 Zhang H, Tan YP, Zhao L, Wang L, Fu NJ, Zheng SP, Shen XF. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1. Cell Death Dis 2020;11:63. [PMID: 31980595 DOI: 10.1038/s41419-020-2227-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
257 Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S. Linifanib vs Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33:172-179. [PMID: 25488963 DOI: 10.1200/jco.2013.54.3298] [Cited by in Crossref: 320] [Cited by in F6Publishing: 181] [Article Influence: 45.7] [Reference Citation Analysis]
258 Fukuda K, Okumura T, Abei M, Fukumitsu N, Ishige K, Mizumoto M, Hasegawa N, Numajiri H, Ohnishi K, Ishikawa H. Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer Sci. 2017;108:497-503. [PMID: 28012214 DOI: 10.1111/cas.13145] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
259 Cusimano A, Puleio R, D'Alessandro N, Loria GR, McCubrey JA, Montalto G, Cervello M. Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. Oncotarget 2015;6:1707-22. [PMID: 25596737 DOI: 10.18632/oncotarget.2738] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
260 Jung S, Shen S, Ye SJ. Dose perturbation and inhomogeneity of multi-arrays of 125I seed-loaded stent for treatment of portal vein tumor thrombosis. Phys Med 2019;66:1-7. [PMID: 31563726 DOI: 10.1016/j.ejmp.2019.09.077] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
261 Tarantino L, Busto G, Nasto A, Fristachi R, Cacace L, Talamo M, Accardo C, Bortone S, Gallo P, Tarantino P, Nasto RA, Di Minno MN, Ambrosino P. Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study. World J Gastroenterol. 2017;23:906-918. [PMID: 28223736 DOI: 10.3748/wjg.v23.i5.906] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
262 Cardoso H, Alves AM, Marques M, Vale AM, Pereira P, Macedo G. Hepatocellular Carcinoma Treatment With Sorafenib: Real-Life Evaluation of Prognostic Factors and a Practical Clue for Patient Management. GE Port J Gastroenterol 2016;23:243-8. [PMID: 28868469 DOI: 10.1016/j.jpge.2016.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
263 de Stefano G, Iodice V, Farella N. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report. J Gastrointest Cancer 2015;46:430-3. [PMID: 25894635 DOI: 10.1007/s12029-015-9720-5] [Reference Citation Analysis]
264 Komatsu S, Kido M, Asari S, Toyama H, Ajiki T, Demizu Y, Terashima K, Okimoto T, Sasaki R, Fukumoto T. Particle radiotherapy, a novel external radiation therapy, versus liver resection for hepatocellular carcinoma accompanied with inferior vena cava tumor thrombus: A matched-pair analysis. Surgery 2017;162:1241-9. [PMID: 29031927 DOI: 10.1016/j.surg.2017.08.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
265 Yen C, Sharma R, Rimassa L, Arizumi T, Bettinger D, Choo HY, Pressiani T, Burlone ME, Pirisi M, Giordano L, Abdulrahman A, Kudo M, Thimme R, Park JW, Pinato DJ. Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study. Liver Cancer 2017;6:313-24. [PMID: 29234635 DOI: 10.1159/000480441] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
266 Lee SW, Lee TY, Peng YC, Yang SS, Yeh HZ, Chang CS. Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status. Medicine (Baltimore) 2019;98:e17692. [PMID: 31689794 DOI: 10.1097/MD.0000000000017692] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
267 Cerrito L, Santopaolo F, Monti F, Pompili M, Gasbarrini A, Ponziani FR. Advances in pharmacotherapeutics for hepatocellular carcinoma. Expert Opin Pharmacother 2021;22:1343-54. [PMID: 33637024 DOI: 10.1080/14656566.2021.1892074] [Reference Citation Analysis]
268 Quintieri L, Selmy M, Indraccolo S. Metabolic effects of antiangiogenic drugs in tumors: therapeutic implications. Biochem Pharmacol 2014;89:162-70. [PMID: 24607274 DOI: 10.1016/j.bcp.2014.02.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
269 Yang Y, Wen F, Li J, Zhang P, Yan W, Hao P, Xia F, Bi F, Li Q. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Int 2015;35:2147-54. [PMID: 25676812 DOI: 10.1111/liv.12805] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
270 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
271 Zhang L, Hu B, Li W, Huang P, Zhang S, Zhong B, Ni C. 125I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review. Cardiovasc Intervent Radiol 2020;43:196-203. [DOI: 10.1007/s00270-019-02346-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
272 Adhoute X, Penaranda G, Naude S, Raoul JL, Perrier H, Bayle O, Monnet O, Beaurain P, Bazin C, Pol B, Folgoc GL, Castellani P, Bronowicki JP, Bourlière M. Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process. Journal of Hepatology 2015;62:855-62. [DOI: 10.1016/j.jhep.2014.11.014] [Cited by in Crossref: 81] [Cited by in F6Publishing: 61] [Article Influence: 13.5] [Reference Citation Analysis]
273 Tan JL, Li F, Yeo JZ, Yong KJ, Bassal MA, Ng GH, Lee MY, Leong CY, Tan HK, Wu CS, Liu BH, Chan TH, Tan ZH, Chan YS, Wang S, Lim ZH, Toh TB, Hooi L, Low KN, Ma S, Kong NR, Stein AJ, Wu Y, Thangavelu MT, Suzuki A, Periyasamy G, Asara JM, Dan YY, Bonney GK, Chow EK, Lu GD, Ng HH, Kanagasundaram Y, Ng SB, Tam WL, Tenen DG, Chai L. New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation. Gastroenterology 2019;157:1615-1629.e17. [PMID: 31446059 DOI: 10.1053/j.gastro.2019.08.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
274 Xiang Z, Bai M, Li G, Zou B, Zhong Z, Gao F, Wu C, Huang M, Zhang F. Safety and efficacy of 125I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation. J Cancer Res Clin Oncol 2019;145:1907-16. [PMID: 31161374 DOI: 10.1007/s00432-019-02943-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
275 Ohki T, Sato K, Yamagami M, Ito D, Yamada T, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. Clin Drug Investig 2015;35:751-9. [PMID: 26446004 DOI: 10.1007/s40261-015-0333-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
276 Hyun MH, Lee YS, Kim JH, Lee CU, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies. Hepatology. 2018;68:977-993. [PMID: 29543988 DOI: 10.1002/hep.29883] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 22.0] [Reference Citation Analysis]
277 Mei J, Li SH, Wang QX, Lu LH, Ling YH, Zou JW, Lin WP, Wen YH, Wei W, Guo RP. Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study. Front Oncol 2020;10:573. [PMID: 32432036 DOI: 10.3389/fonc.2020.00573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
278 Hinrichs JB, Shin H, Kaercher D, Hasdemir D, Murray T, Kaireit T, Lutat C, Vogel A, Meyer BC, Wacker FK, Rodt T. Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. Eur Radiol 2016;26:3447-55. [DOI: 10.1007/s00330-015-4203-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
279 Liu Y, Xue D, Zhang X, Gao F, Sun L, Yang X, Li Y, Zhang Q, Zhu B, Niu S, Huang Y, Hu Y, Wang X. Nomogram for Individualized Prediction of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis on Conservative Treatment. Biomed Res Int 2020;2020:1473718. [PMID: 32149077 DOI: 10.1155/2020/1473718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
280 Yoo GS, Yu JI, Cho S, Jung SH, Han Y, Park S, Oh Y, Lee B, Park HC, Lim DH, Choi MS, Won H. Comparison of clinical outcomes between passive scattering versus pencil-beam scanning proton beam therapy for hepatocellular carcinoma. Radiother Oncol 2020;146:187-93. [PMID: 32179362 DOI: 10.1016/j.radonc.2020.02.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
281 Hai S, Hatano E, Okada T, Uyama N, Suzumura K, Fujimoto J. Is Noncurative Hepatic Resection Justified for Advanced Hepatocellular Carcinoma?. The American Surgeon 2018;84:1938-44. [DOI: 10.1177/000313481808401241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
282 Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: The present and the future. World J Hepatol 2017;9:907-20. [PMID: 28824742 DOI: 10.4254/wjh.v9.i21.907] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 16.8] [Reference Citation Analysis]
283 Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol 2019;25:4360-82. [PMID: 31496618 DOI: 10.3748/wjg.v25.i31.4360] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 19.0] [Reference Citation Analysis]
284 Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. Hepatobiliary Surg Nutr 2018;7:487-9. [PMID: 30652096 DOI: 10.21037/hbsn.2018.10.06] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 7.7] [Reference Citation Analysis]
285 Cao F, Shen L, Qi H, Xie L, Song Z, Chen S, Fan W. Tree-based classification system incorporating the HVTT-PVTT score for personalized management of hepatocellular carcinoma patients with macroscopic vascular invasion. Aging (Albany NY) 2019;11:9544-55. [PMID: 31682230 DOI: 10.18632/aging.102403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
286 Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. World J Gastroenterol. 2014;20:786-794. [PMID: 24574751 DOI: 10.3748/wjg.v20.i3.786] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
287 Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol. 2015;7:521-531. [PMID: 25848475 DOI: 10.4254/wjh.v7.i3.521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
288 Jiang Y, Tang H, Wang Z, Sun Y, Meng W, Wang G, Li H, Yi S, Wang G, Yang Y, Chen G. Two Nomograms to Select Hepatocellular Carcinoma Patients with Macroscopic Vascular Invasion for Hepatic Resection. J Cancer 2018;9:3287-94. [PMID: 30271488 DOI: 10.7150/jca.25899] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
289 Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A. Immunotherapy in Gastrointestinal Cancers. Biomed Res Int. 2017;2017:4346576. [PMID: 28758114 DOI: 10.1155/2017/4346576] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
290 Finn RS, Poon RT, Yau T, Klümpen H, Chen L, Kang Y, Kim T, Gomez-martin C, Rodriguez-lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. Journal of Hepatology 2013;59:1271-7. [DOI: 10.1016/j.jhep.2013.07.029] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.8] [Reference Citation Analysis]
291 Dendy MS, Ludwig JM, Stein SM, Kim HS. Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions. Liver Cancer 2019;8:326-40. [PMID: 31768343 DOI: 10.1159/000494843] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
292 Contratto M, Wu J. Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. World J Gastrointest Oncol 2018;10:108-14. [PMID: 29770170 DOI: 10.4251/wjgo.v10.i5.108] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
293 Lu XJ, Dong J, Ji LJ, Xiao LX, Ling CQ, Zhou J. Tolerability and efficacy of gamma knife radiosurgery on hepatocellular carcinoma with portal vein tumor thrombosis. Oncotarget. 2016;7:3614-3622. [PMID: 26473291 DOI: 10.18632/oncotarget.6118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
294 Zhu Z, Wang X, Yuan K, Huang J, Zeng Y. Transarterial chemoembolization plus iodine-125 implantation for hepatocellular carcinoma: a systematic review and meta-analysis. HPB 2018;20:795-802. [DOI: 10.1016/j.hpb.2018.03.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
295 Lu J, Guo J, Zhu H, Zhu G, Chen L, Teng G. Safety and Efficacy of Irradiation Stent Placement for Malignant Portal Vein Thrombus Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience. Journal of Vascular and Interventional Radiology 2017;28:786-794.e3. [DOI: 10.1016/j.jvir.2017.02.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
296 Zhu B, Sun L, Luo W, Li M, Coy DH, Yu L, Yu W. Activated Notch signaling augments cell growth in hepatocellular carcinoma via up-regulating the nuclear receptor NR4A2. Oncotarget. 2017;8:23289-23302. [PMID: 28423575 DOI: 10.18632/oncotarget.15576] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
297 Raees A, Kamran M, Özkan H, Jafri W. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2021;11:32-40. [PMID: 34316462 DOI: 10.5005/jp-journals-10018-1335] [Reference Citation Analysis]
298 Yoo GS, Ahn WG, Kim SY, Kang W, Choi C, Park HC. Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study. Clin Mol Hepatol 2021;27:144-56. [PMID: 33280350 DOI: 10.3350/cmh.2020.0095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
299 Cheng CC, Chao WT, Shih JH, Lai YS, Hsu YH, Liu YH. Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma. Cancer Chemother Pharmacol 2021;88:143-53. [PMID: 33860837 DOI: 10.1007/s00280-021-04272-8] [Reference Citation Analysis]
300 Rimassa L, Pressiani T, Merle P. Systemic Treatment Options in Hepatocellular Carcinoma. Liver Cancer. 2019;8:427-446. [PMID: 31799201 DOI: 10.1159/000499765] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 16.5] [Reference Citation Analysis]
301 Yokoyama-Mashima S, Yogosawa S, Kanegae Y, Hirooka S, Yoshida S, Horiuchi T, Ohashi T, Yanaga K, Saruta M, Oikawa T, Yoshida K. Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer. Cancer Lett 2019;451:100-9. [PMID: 30851422 DOI: 10.1016/j.canlet.2019.02.046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
302 Choi JW, Kim H, Lee J, Yu SJ, Kim YJ, Yoon J, Jae HJ, Hur S, Lee M, Chung JW. Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. Eur Radiol 2017;27:1448-58. [DOI: 10.1007/s00330-016-4511-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
303 Chen A, Li S, Yao Z, Hu J, Cao J, Topatana W, Juengpanich S, Yu H, Shen J, Chen M. Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A meta-analysis. J Gastroenterol Hepatol 2021;36:302-10. [PMID: 32652685 DOI: 10.1111/jgh.15180] [Reference Citation Analysis]
304 Malfertheiner P, Verslype C, Kolligs FT, Schütte K, Vandecaveye V, Paprottka PM, Ricke J. The effectiveness of selective internal radiation therapy in challenging cases of liver-predominant unresectable hepatocellular carcinoma. Future Oncol 2014;10:17-27. [PMID: 25478762 DOI: 10.2217/fon.14.218] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
305 Titano J, Noor A, Kim E. Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages. Semin Intervent Radiol 2017;34:109-15. [PMID: 28579678 DOI: 10.1055/s-0037-1602709] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
306 Lyu N, Kong Y, Mu L, Lin Y, Li J, Liu Y, Zhang Z, Zheng L, Deng H, Li S, Xie Q, Guo R, Shi M, Xu L, Cai X, Wu P, Zhao M. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. Journal of Hepatology 2018;69:60-9. [DOI: 10.1016/j.jhep.2018.02.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
307 Connell LC, Harding JJ, Abou-Alfa GK. Advanced Hepatocellular Cancer: the Current State of Future Research. Curr Treat Options Oncol. 2016;17:43. [PMID: 27344158 DOI: 10.1007/s11864-016-0415-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
308 Facciorusso A, Paolillo R, Tartaglia N, Ramai D, Mohan BP, Cotsoglou C, Chandan S, Ambrosi A, Bargellini I, Renzulli M, Sacco R. Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: A meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00318-2. [PMID: 34193367 DOI: 10.1016/j.dld.2021.06.003] [Reference Citation Analysis]
309 Sun G, Mackey LV, Coy DH, Yu CY, Sun L. The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch Signaling. J Cancer 2015;6:996-1004. [PMID: 26366213 DOI: 10.7150/jca.12135] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
310 McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer 2018;105:1-9. [PMID: 30384012 DOI: 10.1016/j.ejca.2018.09.031] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
311 Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M, Ellithy M. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 2013;30:655. [PMID: 23824645 DOI: 10.1007/s12032-013-0655-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
312 Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430-3446. [PMID: 27622302 DOI: 10.1002/cncr.30237] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 21.2] [Reference Citation Analysis]
313 Nault J, Ningarhari M, Rebouissou S, Zucman-rossi J. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol 2019;16:544-58. [DOI: 10.1038/s41575-019-0165-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 27.5] [Reference Citation Analysis]
314 Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Kondo S, Morizane C, Ueno H, Satake M, Arai Y, Okusaka T. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. J Gastroenterol 2014;49:932-40. [PMID: 23793266 DOI: 10.1007/s00535-013-0853-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
315 Yang Z, Chen G, Cui Y, Xiao G, Su T, Yu J, Zhang Z, Han Y, Yang K, Jin L. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study. Cancer Biol Ther 2019;20:321-7. [PMID: 30332553 DOI: 10.1080/15384047.2018.1529099] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
316 Woo HY, Heo J. New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol 2015;21:115-21. [PMID: 26157747 DOI: 10.3350/cmh.2015.21.2.115] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
317 Motegi S, Yokoo T, Nozawa R, Azumi R, Kawata Y, Ogawa K, Setsu T, Mizuno KI, Nishino K, Umezu H, Kawai H, Suda T, Terai S. Long-term survival of 11 years with multidisciplinary therapy for hepatocellular carcinoma metastasis to the ovary and peritoneum: a case report. Clin J Gastroenterol 2021;14:1211-20. [PMID: 33978943 DOI: 10.1007/s12328-021-01434-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
318 Dendy MS, Camacho JC, Ludwig JM, Krasinskas AM, Knechtle SJ, Kim HS. Infiltrative Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With a Single High-Dose Y90 Radioembolization and Subsequent Liver Transplantation Without a Recurrence. Transplant Direct 2017;3:e206. [PMID: 28894793 DOI: 10.1097/TXD.0000000000000707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
319 Sparchez Z, Craciun R, Caraiani C, Horhat A, Nenu I, Procopet B, Sparchez M, Stefanescu H, Mocan T. Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward? J Clin Med 2021;10:903. [PMID: 33668839 DOI: 10.3390/jcm10050903] [Reference Citation Analysis]
320 Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KPS, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. OncoTargets and therapy. 2016;773-780. [PMID: 26929648 DOI: 10.2147/ott.s91977] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
321 Bruix J, Takayama T, Mazzaferro V, Chau G-Y, Yang J, Kudo M, Cai J, Poon RT, Han K-H, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Le Berre Marie-Aude, Meinhardt G, Llovet JM, investigators S. Articles Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16: :1344-1354. [PMID: 26361969 DOI: 10.1016/s1470-2045(15)00198-9] [Cited by in Crossref: 436] [Cited by in F6Publishing: 208] [Article Influence: 72.7] [Reference Citation Analysis]
322 Kolly P, Reeves H, Sangro B, Knöpfli M, Candinas D, Dufour J. Assessment of the Hong Kong Liver Cancer Staging System in Europe. Liver Int 2016;36:911-7. [DOI: 10.1111/liv.13045] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
323 Cao P, Jin Q, Feng L, Li H, Qin G, Zhou G. Emerging roles and potential clinical applications of noncoding RNAs in hepatocellular carcinoma. Semin Cancer Biol 2020:S1044-579X(20)30191-7. [PMID: 32931952 DOI: 10.1016/j.semcancer.2020.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
324 Ochi M, Kamoshida T, Ohkawara A, Ohkawara H, Kakinoki N, Hirai S, Yanaka A. Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.World J Gastroenterol. 2018;24:3155-3162. [PMID: 30065561 DOI: 10.3748/wjg.v24.i28.3155] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
325 Cheng Z, Wei-Qi J, Jin D. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer 2020;1874:188382. [PMID: 32522600 DOI: 10.1016/j.bbcan.2020.188382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
326 Kutkowska J, Strzadala L, Rapak A. Sorafenib in Combination with Betulinic Acid Synergistically Induces Cell Cycle Arrest and Inhibits Clonogenic Activity in Pancreatic Ductal Adenocarcinoma Cells. Int J Mol Sci 2018;19:E3234. [PMID: 30347681 DOI: 10.3390/ijms19103234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
327 Leathers JS, Balderramo D, Prieto J, Diehl F, Gonzalez-ballerga E, Ferreiro MR, Carrera E, Barreyro F, Diaz-ferrer J, Singh D, Mattos AZ, Carrilho F, Debes JD. Sorafenib for Treatment of Hepatocellular Carcinoma: A Survival Analysis From the South American Liver Research Network. Journal of Clinical Gastroenterology 2019;53:464-9. [DOI: 10.1097/mcg.0000000000001085] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
328 Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 2018;19:682-693. [PMID: 29625879 DOI: 10.1016/s1470-2045(18)30146-3] [Cited by in Crossref: 170] [Cited by in F6Publishing: 89] [Article Influence: 56.7] [Reference Citation Analysis]
329 Roayaie S, Jibara G, Taouli B, Schwartz M. Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol. 2013;20:3754-3760. [PMID: 23884750 DOI: 10.1245/s10434-013-3074-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
330 Xiang X, Lau W, Wu Z, Zhao C, Ma Y, Xiang B, Zhu J, Zhong J, Li L. Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus:a multicenter study. European Journal of Surgical Oncology 2019;45:1460-7. [DOI: 10.1016/j.ejso.2019.03.042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
331 Yoo GS, Yu JI, Park HC, Hyun D, Jeong WK, Lim HY, Choi MS, Ha SY. Do Biliary Complications after Proton Beam Therapy for Perihilar Hepatocellular Carcinoma Matter? Cancers (Basel) 2020;12:E2395. [PMID: 32847035 DOI: 10.3390/cancers12092395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
332 Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E. Sunitinib vs sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013;31:4067-4075. [PMID: 24081937 DOI: 10.1200/jco.2012.45.8372] [Cited by in Crossref: 447] [Cited by in F6Publishing: 250] [Article Influence: 55.9] [Reference Citation Analysis]
333 Wei Y, Shen N, Wang Z, Yang G, Yi B, Yang N, Qiu Y, Lu J. Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling. Mol Cell Biochem. 2013;381:139-144. [PMID: 23756716 DOI: 10.1007/s11010-013-1695-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
334 Negri F, Missale G, Antoni AD, Porta C. Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. Transl Oncol 2021;14:101153. [PMID: 34144349 DOI: 10.1016/j.tranon.2021.101153] [Reference Citation Analysis]
335 Lau WY, Teoh YL, Win KM, Lee RC, de Villa VH, Kim YH, Liang PC, Santos-Ocampo RS, Lo RH, Lim KB, Tai DW, Ng DC, Irani FG, Gogna A, Chow PK. Current role of selective internal radiation with yttrium-90 in liver tumors. Future Oncol 2016;12:1193-204. [PMID: 27007495 DOI: 10.2217/fon-2016-0035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
336 Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013;58:2188-97. [PMID: 23512791 DOI: 10.1002/hep.26382] [Cited by in Crossref: 109] [Cited by in F6Publishing: 97] [Article Influence: 13.6] [Reference Citation Analysis]
337 Lozano E, Herraez E, Briz O, Robledo VS, Hernandez-Iglesias J, Gonzalez-Hernandez A, Marin JJ. Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. Biomed Res Int 2013;2013:692071. [PMID: 23984399 DOI: 10.1155/2013/692071] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
338 Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol 2019;25:2416-29. [PMID: 31171886 DOI: 10.3748/wjg.v25.i20.2416] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
339 Que J, Lin CH, Lin LC, Ho CH. Challenges of BCLC stage C hepatocellular carcinoma: Results of a single-institutional experience on stereotactic body radiation therapy. Medicine (Baltimore) 2020;99:e21561. [PMID: 32769898 DOI: 10.1097/MD.0000000000021561] [Reference Citation Analysis]
340 Feng X, Song P, Bie P, Jiang P, Ma K, Li X, Wang S, Wang Z, Tang W, Zheng S. Des-γ-Carboxyprothrombin Plasma Level in Diagnosis of Hepatocellular Carcinoma in a Chinese Population Undergoing Surgery. Med Sci Monit 2016;22:1663-72. [PMID: 27187589 DOI: 10.12659/msm.895483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
341 de la Torre MA, Buades-Mateu J, de la Rosa PA, Lué A, Bustamante FJ, Serrano MT, Testillano M, Lorente S, Arenas JI, Gil C, Iñarrairaegui M, Sangro B. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. Liver Int 2016;36:1206-12. [PMID: 26910784 DOI: 10.1111/liv.13098] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
342 King J, Palmer DH, Johnson P, Ross P, Hubner RA, Sumpter K, Darby S, Braconi C, Iwuji C, Swinson D, Collins P, Patel K, Nobes J, Muazzam I, Blesing C, Kirkwood A, Nash S, Meyer T. Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit. Clin Oncol (R Coll Radiol). 2017;29:256-262. [PMID: 27964898 DOI: 10.1016/j.clon.2016.11.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
343 Eatrides J, Wang E, Kothari N, Kim R. Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma. Cancer Control. 2017;24:1073274817729243. [PMID: 28975834 DOI: 10.1177/1073274817729243] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
344 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I, Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol 2018;10:571-84. [PMID: 30310535 DOI: 10.4254/wjh.v10.i9.571] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
345 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 75] [Article Influence: 90.0] [Reference Citation Analysis]
346 Abou-Alfa GK. Approaching the era of personalised therapy for liver cancer? Lancet Oncol 2013;14:7-8. [PMID: 23182626 DOI: 10.1016/S1470-2045(12)70519-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
347 Dewdney B, Roberts A, Qiao L, George J, Hebbard L. A Sweet Connection? Fructose's Role in Hepatocellular Carcinoma. Biomolecules 2020;10:E496. [PMID: 32218179 DOI: 10.3390/biom10040496] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
348 Akutsu N, Sasaki S, Takagi H, Motoya M, Shitani M, Igarashi M, Hirayama D, Wakasugi H, Yamamoto H, Kaneto H, Yonezawa K, Yawata A, Adachi T, Hamamoto Y, Shinomura Y. Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. Int J Clin Oncol 2015;20:105-10. [PMID: 24744262 DOI: 10.1007/s10147-014-0691-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
349 Ding XX, Zhu QG, Zhang SM, Guan L, Li T, Zhang L, Wang SY, Ren WL, Chen XM, Zhao J, Lin S, Liu ZZ, Bai YX, He B, Zhang HQ. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget. 2017;8:55715-55730. [PMID: 28903454 DOI: 10.18632/oncotarget.18382] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 10.3] [Reference Citation Analysis]
350 Nakatake R, Kaibori M, Nakamura Y, Tanaka Y, Matushima H, Okumura T, Murakami T, Ino Y, Todo T, Kon M. Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice. Cancer Sci 2018;109:600-10. [PMID: 29288515 DOI: 10.1111/cas.13492] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
351 Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, Hinrichs JB, Düber C, Galle PR, Lang H, Weinmann A. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS One 2021;16:e0249426. [PMID: 33961627 DOI: 10.1371/journal.pone.0249426] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
352 Daniele B, Croitoru A, Papandreou C, Bronowicki J, Mathurin P, Serejo F, Stål P, Turnes J, Ratziu V, Bodoky G. Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. Future Oncology 2015;11:2553-62. [DOI: 10.2217/fon.15.163] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
353 Raoul JL, Gilabert M, Adhoute X, Edeline J. An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma. Expert Opin Pharmacother. 2017;18:1467-1476. [PMID: 28893090 DOI: 10.1080/14656566.2017.1378346] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
354 Kamil F, Rowe JH. How does the tumor microenvironment play a role in hepatobiliary tumors? J Gastrointest Oncol 2018;9:180-95. [PMID: 29564184 DOI: 10.21037/jgo.2017.06.09] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
355 Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res. 2013;43:147-154. [PMID: 23145926 DOI: 10.1111/j.1872-034x.2012.01113.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 75] [Article Influence: 12.6] [Reference Citation Analysis]
356 Nagamatsu H, Sumie S, Niizeki T, Tajiri N, Iwamoto H, Aino H, Nakano M, Shimose S, Satani M, Okamura S. Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study. Cancer Chemother Pharmacol. 2016;77:243-250. [PMID: 26754678 DOI: 10.1007/s00280-015-2892-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
357 Ziogas DC, Papadatos-pastos D, Thillai K, Korantzis I, Chowdhury R, Suddle A, O’grady J, Al-khadimi G, Allen N, Heaton N, Ross PJ, Sarker D. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. European Journal of Gastroenterology & Hepatology 2017;29:48-55. [DOI: 10.1097/meg.0000000000000739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
358 Kondo M, Morimoto M, Ishii T, Nozaki A, Fukuda H, Numata K, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Shibuya A, Okuse C, Suzuki M, Sakamaki K, Morita S, Maeda S, Tanaka K. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting. J Dig Dis 2015;16:143-51. [PMID: 25495751 DOI: 10.1111/1751-2980.12221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
359 Kennedy A. Radioembolization of hepatic tumors. J Gastrointest Oncol. 2014;5:178-189. [PMID: 24982766 DOI: 10.3978/j.issn.2078-6891.2014.037] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
360 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 701] [Article Influence: 156.2] [Reference Citation Analysis]
361 Yu SJ, Kim YJ. Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. World J Hepatol. 2015;7:1553-1561. [PMID: 26085914 DOI: 10.4254/wjh.v7.i11.1553] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
362 Assalino M, Terraz S, Grat M, Lai Q, Vachharajani N, Gringeri E, Bongini MA, Kulik L, Tabrizian P, Agopian V, Mehta N, Brustia R, Vitali GC, Andres A, Berney T, Mazzaferro V, Compagnon P, Majno P, Cillo U, Chapman W, Zieniewicz K, Scatton O, Toso C. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study. Transpl Int 2020;33:567-75. [PMID: 31994238 DOI: 10.1111/tri.13586] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
363 Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther 2020;5:146. [PMID: 32782275 DOI: 10.1038/s41392-020-00264-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 23.0] [Reference Citation Analysis]
364 Casadei Gardini A, Frassineti GL, Foschi FG, Ercolani G, Ulivi P. Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials. Dig Liver Dis. 2017;49:943-944. [PMID: 28546063 DOI: 10.1016/j.dld.2017.04.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
365 Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q. PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. Nat Commun 2019;10:2484. [PMID: 31171773 DOI: 10.1038/s41467-019-10127-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
366 Li J, Qiu X, Guo W, Yan B, Zhang S. Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma. Med Oncol. 2015;32:238. [PMID: 26330362 DOI: 10.1007/s12032-015-0684-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
367 Cheng JW, Lv Y. New progress of non-surgical treatments for hepatocellular carcinoma. Med Oncol 2013;30:381. [PMID: 23292867 DOI: 10.1007/s12032-012-0381-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
368 Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. Liver Cancer 2019;8:78-91. [PMID: 31019899 DOI: 10.1159/000489791] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
369 Piscaglia F, Salvatore V, Venerandi L. Field practice studies on sorafenib: lessons in systemic treatment of hepatocellular carcinoma. Dig Liver Dis. 2013;45:367-368. [PMID: 23562444 DOI: 10.1016/j.dld.2013.02.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
370 Yu Z, Feng H, Zhuo Y, Li M, Zhu X, Huang L, Zhang X, Zhou Z, Zheng C, Jiang Y, Le F, Yu DY, Cheng AS, Sun X, Gao Y. Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation. Cell Oncol (Dordr) 2020;43:1129-45. [PMID: 32623699 DOI: 10.1007/s13402-020-00546-0] [Reference Citation Analysis]
371 Cho YY, Lee M, Kim HC, Chung JW, Kim YH, Gwak GY, Bae SH, Kim do Y, Heo J, Kim YJ. Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. PLoS One. 2016;11:e0154986. [PMID: 27149067 DOI: 10.1371/journal.pone.0154986] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
372 Kudo M, Trevisani F, Abou-Alfa GK, Rimassa L. Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. Liver Cancer. 2016;6:16-26. [PMID: 27995084 DOI: 10.1159/000449343] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 13.0] [Reference Citation Analysis]
373 Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103. [PMID: 28744453 DOI: 10.2147/JHC.S106529] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
374 Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011649. [PMID: 28281295 DOI: 10.1002/14651858.cd011649.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
375 Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, Mariano-Goulart D, Amaddeo G, Palard X, Hollebecque A, Kafrouni M, Regnault H, Boudjema K, Grimaldi S, Fourcade M, Kobeiter H, Vibert E, Le Sourd S, Piron L, Sommacale D, Laffont S, Campillo-Gimenez B, Rolland Y; DOSISPHERE-01 Study Group. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:17-29. [PMID: 33166497 DOI: 10.1016/S2468-1253(20)30290-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 25.0] [Reference Citation Analysis]
376 Juárez-Hernández E, Motola-Kuba D, Chávez-Tapia NC, Uribe M, Barbero Becerra V. Biomarkers in hepatocellular carcinoma: an overview. Expert Rev Gastroenterol Hepatol 2017;11:549-58. [PMID: 28347162 DOI: 10.1080/17474124.2017.1311785] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
377 Nault J, Nkontchou G, Nahon P, Grando V, Bourcier V, Barge S, Ziol M, Sellier N, Ganne-carrie N, Seror O. Percutaneous Treatment of Localized Infiltrative Hepatocellular Carcinoma Developing on Cirrhosis. Ann Surg Oncol 2016;23:1906-15. [DOI: 10.1245/s10434-015-5064-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
378 Abou-Alfa GK, Venook AP. The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached? Lancet Oncol. 2013;14:e283-e288. [PMID: 23725711 DOI: 10.1016/s1470-2045(13)70161-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
379 Casadei Gardini A, Marisi G, Scarpi E, Scartozzi M, Faloppi L, Silvestris N, Masi G, Vivaldi C, Brunetti O, Tamberi S. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opin Pharmacother. 2015;16:2719-2725. [PMID: 26513009 DOI: 10.1517/14656566.2015.1102887] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 7.2] [Reference Citation Analysis]
380 Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14:55-63. [PMID: 23182627 DOI: 10.1016/s1470-2045(12)70490-4] [Cited by in Crossref: 397] [Cited by in F6Publishing: 212] [Article Influence: 44.1] [Reference Citation Analysis]
381 Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Kubo S, Sakamoto M, Nakashima O, Kumada T, Kokudo N;  Liver Cancer Study Group of Japan. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey. Hepatology. 2017;66:510-517. [PMID: 28437844 DOI: 10.1002/hep.29225] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 15.5] [Reference Citation Analysis]
382 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Reference Citation Analysis]
383 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 233] [Article Influence: 35.3] [Reference Citation Analysis]
384 Sangro B. Evidence-based integration of selective internal radiation therapy into hepatocellular carcinoma management. Future Oncol 2014;10:7-11. [PMID: 25478760 DOI: 10.2217/fon.14.216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
385 Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol 2016;8:703-15. [PMID: 27330679 DOI: 10.4254/wjh.v8.i17.703] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
386 Peng S, Zhao Y, Xu F, Jia C, Xu Y, Dai C. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. PLoS One. 2014;9:e112530. [PMID: 25460347 DOI: 10.1371/journal.pone.0112530] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
387 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 418] [Cited by in F6Publishing: 223] [Article Influence: 83.6] [Reference Citation Analysis]
388 Li LQ, Zhou Y, Huang Y, Liang P, Liang SX, Su TS. Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Int 2021;15:630-41. [PMID: 33818714 DOI: 10.1007/s12072-021-10173-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
389 Mikhail S, Cosgrove D, Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives. Expert Rev Anticancer Ther. 2014;14:1205-1218. [PMID: 25199765 DOI: 10.1586/14737140.2014.949246] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
390 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. Oncol Lett 2017;14:1637-47. [PMID: 28789390 DOI: 10.3892/ol.2017.6287] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
391 Lee S, Kim BK, Kim SU, Park Y, Chang S, Park JY, Kim do Y, Ahn SH, Chon CY, Han KH. Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. PLoS One. 2013;8:e77240. [PMID: 24155932 DOI: 10.1371/journal.pone.0077240] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
392 Saha SK, Yin Y, Kim K, Yang GM, Dayem AA, Choi HY, Cho SG. Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells. Int J Mol Sci 2017;18:E1048. [PMID: 28498322 DOI: 10.3390/ijms18051048] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
393 Reataza M, Imagawa DK. Advances in managing hepatocellular carcinoma. Front Med. 2014;8:175-189. [PMID: 24810646 DOI: 10.1007/s11684-014-0332-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
394 Fujino H, Kimura T, Aikata H, Miyaki D, Kawaoka T, Kan H, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Takahashi S, Yoshimatsu R, Yamagami T, Kenjo M, Nagata Y, Awai K, Chayama K. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Hepatol Res. 2015;45:607-617. [PMID: 25052365 DOI: 10.1111/hepr.12392] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
395 Choi JY, Yu JI, Park HC, David Kwon CH, Kim JM, Joh J, Choi G, Park JB, Kim SJ, Lee SH, Cho W, Lee KW, Na B, Oh DK, Lee N, Cho CW, Lee S, Lee S. The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus. Liver Transpl 2017;23:545-51. [DOI: 10.1002/lt.24729] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
396 Sakamoto K, Nagano H. Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus. Hepatol Res. 2017;47:957-962. [PMID: 28618075 DOI: 10.1111/hepr.12923] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
397 Keating GM. Sorafenib: A Review in Hepatocellular Carcinoma. Target Oncol. 2017;12:243-253. [PMID: 28299600 DOI: 10.1007/s11523-017-0484-7] [Cited by in Crossref: 95] [Cited by in F6Publishing: 85] [Article Influence: 23.8] [Reference Citation Analysis]
398 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology 2017;67:173-83. [DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 17.3] [Reference Citation Analysis]
399 Reig M, Torres F, Rodriguez-lope C, Forner A, Llarch N, Rimola J, Darnell A, Ríos J, Ayuso C, Bruix J. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. Journal of Hepatology 2014;61:318-24. [DOI: 10.1016/j.jhep.2014.03.030] [Cited by in Crossref: 146] [Cited by in F6Publishing: 138] [Article Influence: 20.9] [Reference Citation Analysis]
400 Hasskarl J. Sorafenib: targeting multiple tyrosine kinases in cancer. Recent Results Cancer Res 2014;201:145-64. [PMID: 24756790 DOI: 10.1007/978-3-642-54490-3_8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
401 Zhong JH. The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma. Tumour Biol. 2015;36:8271-8272. [PMID: 26499777 DOI: 10.1007/s13277-015-4279-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
402 Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol. 2015;21:10327-10335. [PMID: 26420959 DOI: 10.3748/wjg.v21.i36.10327] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 47] [Article Influence: 9.8] [Reference Citation Analysis]
403 Wan X, Zhai X, Yan Z, Yang P, Li J, Wu D, Wang K, Xia Y, Shen F. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. Oncotarget 2016;7:83806-16. [PMID: 27566566 DOI: 10.18632/oncotarget.11514] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
404 Katayama K, Imai T, Abe Y, Nawa T, Maeda N, Nakanishi K, Wada H, Fukui K, Ito Y, Yokota I, Ohkawa K. Number of Nodules but not Size of Hepatocellular Carcinoma Can Predict Refractoriness to Transarterial Chemoembolization and Poor Prognosis. J Clin Med Res 2018;10:765-71. [PMID: 30214648 DOI: 10.14740/jocmr3559w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
405 Abdel-rahman O, Fouad M. Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review. Expert Review of Anticancer Therapy 2014;15:165-82. [DOI: 10.1586/14737140.2015.978295] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
406 Mishra M, Jayal P, Karande AA, Chandra N. Identification of a co-target for enhancing efficacy of sorafenib in HCC through a quantitative modeling approach. FEBS J 2018;285:3977-92. [PMID: 30136368 DOI: 10.1111/febs.14641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
407 Bogorad RL, Yin H, Zeigerer A, Nonaka H, Ruda VM, Zerial M, Anderson DG, Koteliansky V. Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice. Nat Commun. 2014;5:3869. [PMID: 24844798 DOI: 10.1038/ncomms4869] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 7.6] [Reference Citation Analysis]
408 Llovet JM. Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma. Cancer Cell. 2014;25:560-562. [PMID: 24823635 DOI: 10.1016/j.ccr.2014.04.019] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
409 Armengol C, Sarrias MR, Sala M. Hepatocellular carcinoma: Present and future. Med Clin (Barc). 2018;150:390-397. [PMID: 29096967 DOI: 10.1016/j.medcli.2017.08.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
410 Fukumoto T, Kido M, Takebe A, Tanaka M, Kinoshita H, Kuramitsu K, Komatsu S, Tsugawa D, Goto T, Asari S, Toyama H, Ajiki T, Ku Y. New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch. Surg Today. 2017;47:1094-1103. [PMID: 28324163 DOI: 10.1007/s00595-017-1507-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
411 Suganya V, Anuradha V. In silico molecular docking of astaxanthin and sorafenib with different apoptotic proteins involved in hepatocellular carcinoma. Biocatalysis and Agricultural Biotechnology 2019;19:101076. [DOI: 10.1016/j.bcab.2019.101076] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
412 Pinato DJ, Brown MW, Trousil S, Aboagye EO, Beaumont J, Zhang H, Coley HM, Mauri FA, Sharma R. Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma. Br J Cancer 2019;120:512-21. [PMID: 30765873 DOI: 10.1038/s41416-018-0373-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
413 Onishi H, Nouso K, Nakamura S, Katsui K, Wada N, Morimoto Y, Miyahara K, Takeuchi Y, Kuwaki K, Yasunaka T. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. Hepatol Int. 2015;9:105-112. [PMID: 25788384 DOI: 10.1007/s12072-014-9592-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
414 Branco F, Alencar RS, Volt F, Sartori G, Dode A, Kikuchi L, Tani CM, Chagas AL, Pfiffer T, Hoff P, Carrilho FJ, Alves de Mattos A. The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib. Annals of Hepatology 2017;16:263-8. [DOI: 10.5604/16652681.1231587] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
415 Mokdad AA, Zhu H, Beg MS, Arriaga Y, Dowell JE, Singal AG, Yopp AC. Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial. Targ Oncol 2019;14:541-50. [DOI: 10.1007/s11523-019-00663-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
416 Chang Lee R, Tebbutt N. Systemic treatment of advanced hepatocellular cancer: new hope on the horizon. Expert Rev Anticancer Ther 2019;19:343-53. [PMID: 30793991 DOI: 10.1080/14737140.2019.1585245] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
417 Edeline J, Gilabert M, Garin E, Boucher E, Raoul JL. Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. Liver Cancer 2015;4:16-25. [PMID: 26020026 DOI: 10.1159/000343878] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
418 Yu Z, Gao YQ, Feng H, Lee YY, Li MS, Tian Y, Go MY, Yu DY, Cheung YS, Lai PB. Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis. Gut. 2014;63:1793-1804. [PMID: 24440987 DOI: 10.1136/gutjnl-2013-305584] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
419 Koga Y, Beppu T, Imai K, Kuramoto K, Miyata T, Kitano Y, Nakagawa S, Okabe H, Okabe K, Yamashita YI, Chikamoto A, Baba H. Complete remission of advanced hepatocellular carcinoma following transient chemoembolization and portal vein ligation. Surg Case Rep 2018;4:102. [PMID: 30159613 DOI: 10.1186/s40792-018-0510-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
420 Kaneko S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Takeguchi T, Takeguchi Y, Nagano T, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Hoshi A, Kurosaki M, Izumi N. Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. Hepatol Res 2020;50:1375-85. [DOI: 10.1111/hepr.13567] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
421 Tsuda T, Kaibori M, Hishikawa H, Nakatake R, Okumura T, Ozeki E, Hara I, Morimoto Y, Yoshii K, Kon M. Near-infrared fluorescence imaging and photodynamic therapy with indocyanine green lactosome has antineoplastic effects for hepatocellular carcinoma. PLoS One 2017;12:e0183527. [PMID: 28859104 DOI: 10.1371/journal.pone.0183527] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
422 Cheng S, Chen M, Cai J, Sun J, Guo R, Bi X, Lau WY, Wu M. Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer 2020;9:28-40. [PMID: 32071907 DOI: 10.1159/000503685] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
423 Zhong J, Lu S, Wang Y, Ma L, Li L. Intermediate-stage HCC—upfront resection can be feasible. Nat Rev Clin Oncol 2015;12:295-295. [DOI: 10.1038/nrclinonc.2014.122-c3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
424 Kanojia D, Garg M, Martinez J, M T A, Luty SB, Doan NB, Said JW, Forscher C, Tyner JW, Koeffler HP. Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. J Hematol Oncol 2017;10:173. [PMID: 29132397 DOI: 10.1186/s13045-017-0540-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
425 Yu Y, Feng M. Radiotherapy for Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:277-87. [PMID: 30309638 DOI: 10.1016/j.semradonc.2018.06.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
426 Sposito C, Mazzaferro V. Reply to: "Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue". J Hepatol 2014;60:682-3. [PMID: 24216444 DOI: 10.1016/j.jhep.2013.10.032] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
427 de la Torre-aláez M, Jordán-iborra C, Casadei-gardini A, Bilbao JI, Rodriguez-fraile M, Sancho L, D’avola D, Herrero JI, Iñarrairaegui M, Sangro B. The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT. Cardiovasc Intervent Radiol 2020;43:1165-72. [DOI: 10.1007/s00270-020-02444-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
428 Samawi HH, Sim HW, Chan KK, Alghamdi MA, Lee-Ying RM, Knox JJ, Gill P, Romagnino A, Batuyong E, Ko YJ, Davies JM, Lim HJ, Cheung WY, Tam VC; CHORD Consortium. Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database. Cancer Med 2018. [PMID: 29766659 DOI: 10.1002/cam4.1493] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
429 Labenz C, Prenosil V, Koch S, Huber Y, Marquardt JU, Schattenberg JM, Galle PR, Weinmann A, Wörns MA. Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Dig Dis 2018;36:78-88. [PMID: 28675895 DOI: 10.1159/000477578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
430 Lim S, Han J, Kim GM, Han KH, Choi HJ. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. J Gastroenterol Hepatol 2015;30:1024-31. [PMID: 25611175 DOI: 10.1111/jgh.12898] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
431 Liu X, Qin S. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. Oncologist 2019;24:S3-S10. [PMID: 30819826 DOI: 10.1634/theoncologist.2019-IO-S1-s01] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 24.0] [Reference Citation Analysis]
432 Moriguchi M, Furuta M, Itoh Y. A Review of Non-operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus. J Clin Transl Hepatol 2017;5:177-83. [PMID: 28660156 DOI: 10.14218/JCTH.2016.00075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
433 Takeda H, Nishikawa H, Osaki Y, Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, Izumi N. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. Liver Int. 2015;35:1581-1589. [PMID: 24836552 DOI: 10.1111/liv.12591] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
434 Grieb BC, Goff LW, Goyal L, Denlinger CS. Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. Am Soc Clin Oncol Educ Book 2019;39:248-60. [PMID: 31099615 DOI: 10.1200/EDBK_237555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
435 Yamashima M, Miyaaki H, Honda T, Shibata H, Miuma S, Taura N, Nakao K. Significance of psoas muscle thickness as an indicator of muscle atrophy in patients with hepatocellular carcinoma treated with sorafenib. Mol Clin Oncol 2017;7:449-53. [PMID: 28781818 DOI: 10.3892/mco.2017.1321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
436 Piguet AC, Medová M, Keogh A, Glück AA, Aebersold DM, Dufour JF, Zimmer Y. Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer. Genes Cancer 2015;6:317-27. [PMID: 26413215 DOI: 10.18632/genesandcancer.74] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
437 Hatano E, Uemoto S, Yamaue H, Yamamoto M; the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Jap. J Hepatobiliary Pancreat Sci 2018;25:395-402. [DOI: 10.1002/jhbp.574] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
438 Torimura T, Iwamoto H. Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. Clin Mol Hepatol 2021;27:236-45. [PMID: 33317248 DOI: 10.3350/cmh.2020.0204] [Reference Citation Analysis]
439 Ponziani FR, Bhoori S, Germini A, Bongini M, Flores M, Sposito C, Facciorusso A, Gasbarrini A, Mazzaferro V. Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. Liver Int 2016;36:1033-42. [PMID: 26709844 DOI: 10.1111/liv.13052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
440 Giannini EG, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, Felder M, Ciccarese F, Foschi FG, Sacco R, Svegliati Baroni G, Farinati F, Rapaccini GL, Olivani A, Gasbarrini A, Di Marco M, Morisco F, Zoli M, Masotto A, Borzio F, Benvegnù L, Marra F, Colecchia A, Nardone G, Bernardi M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology 2018;67:1784-96. [DOI: 10.1002/hep.29668] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 16.3] [Reference Citation Analysis]
441 Peixoto RD, Renouf DJ, Gill S, Cheung WY, Lim HJ. Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. J Gastrointest Oncol 2014;5:259-64. [PMID: 25083298 DOI: 10.3978/j.issn.2078-6891.2014.036] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
442 Wang ZX, Li J, Wang EX, Xia DD, Bai W, Wang QH, Yuan J, Li XM, Niu J, Yin ZX, Xia JL, Fan DM, Han GH. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization. World J Gastroenterol 2020;26:1805-19. [PMID: 32351295 DOI: 10.3748/wjg.v26.i15.1805] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
443 Tang Z, Kang M, Zhang B, Chen J, Fang H, Ye Q, Jiang B, Wu Y. Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma. Tumori 2017;103:286-91. [PMID: 28058713 DOI: 10.5301/tj.5000585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]